

## **Mepolizumab induced changes in nasal methylome and transcriptome to predict response in asthma**

<sup>1,2</sup>Kamini Rakkar, <sup>1,3</sup>Yik Lam Pang, <sup>1,2</sup>Poojitha Rajasekar, <sup>1,2</sup>Michael A Portelli, <sup>1,2</sup>Robert J Hall, <sup>1,2</sup>Rachel L Clifford, <sup>1,3</sup>Dominick Shaw and <sup>1,2</sup>Ian Sayers

<sup>1</sup>Centre for Respiratory Research, National Institute for Health Research Nottingham, Biomedical Research Centre, School of Medicine, <sup>2</sup>Nottingham University Biodiscovery Institute & <sup>3</sup>Clinical Sciences Building, City Hospital, University of Nottingham, Nottingham, United Kingdom

Corresponding author

Kamini Rakkar

Biodiscovery Institute, Science Road, University of Nottingham, NG7 2RD

kamini.rakkar2@nottingham.ac.uk

### **Contributions**

IS, DS and YLP designed the study. KR processed samples, extracted the RNA and DNA and analysed the data. PR and RLC co-analysed the DNA methylation data. MAP and RH co-analysed the RNA sequencing data. All authors contributed to the writing of the manuscript.

### **Sources of funding**

Nottingham NIHR Biomedical Research Centre and Nottingham Universities Hospitals Charity. RC was funded by University of Nottingham Anne McLaren fellowship.

Running title: Mepolizumab changes gene expression in the nose

Descriptor: Asthma Genetics

Total word count: 3237

## **Abstract**

### **Rationale**

Mepolizumab is effective for a subset of severe asthma patients in reducing exacerbation frequency. Discovery of a predictive/early marker accurately identifying patients that will have a long-term beneficial clinical response would enable targeting of treatment.

### **Objectives**

We aimed to characterise the nasal methylome and transcriptome post Mepolizumab and identify signatures related to responder/non-responder status.

### **Methods**

Nasal brushes were taken at baseline (pre-drug) and following 3 months of treatment with Mepolizumab from patients with severe asthma. Both DNA and RNA were extracted. Gene expression was investigated using poly-A RNA sequencing (25M reads) and DNA methylation analysed using the EPIC Array.

### **Measurements and Main Results**

27 paired samples were included, 17 patients were clinical responders and 10 were non-responders at one year. Differential gene expression and DNA methylation analyses identified 6719 genes and 53 CpG sites respectively that changed in response to Mepolizumab. There were 1784 genes which were unique to responders and 893 genes unique to non-responders. Pathway analyses revealed unique gene expression signatures. Respiratory disease associations and regulators of ongoing T2 inflammation pathway were still active in non-responders, and there was an inhibition of neutrophil activation pathways in responders.

### **Conclusions**

There was a significant change in both the transcriptome and methylome in the nasal epithelium in patients three months post-Mepolizumab therapy suggesting broad effects on the airway epithelium in severe asthma. Responder and non-responder group analyses indicate there is a responder-specific gene expression profile that may aid in predicting response at one year.

Abstract word count: 244

Key words: Genetics, Methylation, Interleukin-5, Inflammation, Airway

## Introduction

Asthma affects an estimated 300 million people worldwide and was responsible for 21.6 million disability-adjusted life years in 2019 (1). Globally, severe asthma affects between 3-10% of all patients with asthma (2). In severe asthma, symptoms are usually uncontrolled and exacerbation frequency is high, despite the high dose of medication, including inhaled and oral corticosteroids (2). For some, monoclonal antibody therapy is an option and has been used successfully in several large studies, reducing exacerbation frequency and maintenance oral corticosteroid use (3).

Mepolizumab is an injectable anti-IL5 monoclonal antibody, that prevents the binding of IL5 to its surface receptor on eosinophils (4). It reduces exacerbation frequency and steroid burden (5), however the impact on the airway, particularly at the gene level has not been investigated. In addition, typically a third of patients fail to respond to treatment as seen in real-world studies (6). In the UK, current National Institute for Health and Care Excellence (NICE) guidelines determine efficacy after one year of treatment, based on a clinically significant reduction in exacerbations or continuous oral corticosteroid use (TA671 2021). For patients who do not respond, the duration of medication burden is unnecessary and prevents switching to another monoclonal antibody class, of which there are several. It also costs the NHS time and money.

With additional anti-IL5/IL5R therapies (Reslizumab) and Benralizumab and other biologics targeting separate pathways such as Omalizumab (anti-IgE) and Dupilumab (anti-IL4 and IL13) also available, it is important to investigate biomarkers which may be able to predict early responses to a specific drug, and therefore enable better pharmacological management of patients. Furthermore, investigation of molecular mechanisms may uncover why some patients do not respond to treatment and provide greater understanding of asthma.

Transcriptomic analysis of the airway epithelium is proving a useful tool to both understand asthma pathogenesis and the molecular characterization of responders to specific drugs such as inhaled corticosteroids (7). More recently, the nasal epithelium has shown utility in understanding asthma and drug responses (8) and provides an easy but relevant option in investigating molecular mechanisms of the airway epithelium.

We aimed to explore any changes in gene expression and/or DNA methylation in response to Mepolizumab therapy in the nasal epithelium to provide novel drug mechanistic insight. Furthermore, we aimed to detect a predictive or early gene expression and/or DNA methylation signature that could identify responders or non-responders and therefore enable Mepolizumab therapy to be targeted to those most likely to benefit. Asthma has previously been defined with respect to Type 1 (T1) or Type 2 (T2) inflammation, characterised by high neutrophil (T1) or high eosinophil, immunoglobulin E and fractional exhaled nitric oxide (T2) levels. However new data is suggesting a more nuanced approach is required, a statement supported by this study. Our findings suggest there is a significant transcriptional response to Mepolizumab in the nasal epithelium which is, at least in part, mediated by changes in DNA methylation. We also identified a unique gene expression signature in patients that had a clinically significant response at one year.

## **Methods**

Full methods and statistical analyses are listed in the Supplement. Flow diagram indicating sample and analysis pipeline is in Figure 1.

### **Recruitment**

The PROCLAIM study (Poor Response to monoclonal therapy in asthma) enrolled 42 patients with severe asthma who matched the UK National Health Service (NHS) criteria for receiving Mepolizumab (TA431). Patients were recruited between January 2019 and June 2020. The study was approved by the Medical Ethics Committee (REC18/EM/0268). 27 patients' data was used in this analysis due to patient withdrawal (4 patients) and unavailability of matched nasal brush samples for baseline and 3 months post-Mepolizumab treatment (11 patients).

### **Sample collection**

Nasal brushes were taken at baseline (pre-drug) and 3-months of Mepolizumab treatment. RNA and DNA were extracted with a dual RNA/DNA Purification (Norgen Biotek Corp.).

### **Responder group allocation**

Responders were defined as patients who had a 50% reduction in oral corticoid steroid use or 50% reduction in exacerbation frequency after one year of Mepolizumab therapy as per NICE guidelines TA431 (2017). For consistency and adherence to protocol, we did not alter the study's definition of clinical response when NICE published the new TA671 (2021).

### **RNA sequencing**

Gene expression was determined through stranded paired end polyA RNA sequencing (Oxford Genomics) using Illumina v1.5 chemistry and the NovaSeq6000 at a minimum of 25M reads per sample.

### **DNA methylation**

DNA methylation was determined through the Illumina Infinium MethylationEPIC Bead Chip Array (Diagenode) which covers 850,000 methylation sites.

## **Results**

### **Responders and non-responders show no significant differences in clinical or demographic features at baseline**

The patient cohort had a median age of 57 years and predominance of females (62%) in line with other severe asthma cohorts (9). As expected, patients had at least one comorbidity (90%) and asthma control questionnaire (ACQ6) scores were in line with severe asthma patients with average scores >3. Similarly, clinical features such as lung function measured by FEV<sub>1</sub>/FVC ratios are <70% and eosinophil levels are 0.55 x10<sup>9</sup>/L or higher, indicative of severe asthma patients (Table 1).

### **The nasal cell composition following Mepolizumab treatment is unaltered**

After filtering and normalisation 684,807 probes were used in the methylation analysis (Supplement Figure 1). A reference dataset (EpiDISH) was used to determine indirectly the cell type composition of the nasal brush samples using DNA methylation data. Epithelial cell, fibroblast, and immune cell markers were analysed. There were no significant differences in inferred cell type composition between baseline and post-Mepolizumab therapy and between responder and non-responder groups (Supplement Figure 2). Epithelial cells were the largest observed population of cells.

### **Mepolizumab induces significant changes in gene expression in the nasal epithelium**

Principal component analysis of gene expression shows distinct clustering of patients post-Mepolizumab therapy (red dots) compared to a more heterogenous distribution pre-treatment (blue dots, Figure 2A). A total of 2547 genes were down-regulated, and 4172 genes were up-regulated following 3 months treatment in all patients (Figure 2B). Expression values of these genes in each patient sample distinctly shows the changes in expression after therapy (Figure 2C). A list of differentially expressed genes is provided (Supplement Table 1).

### **Mepolizumab-induced changes in gene expression are associated with downstream viral disease**

Disease association pathway analysis of the gene expression changes following Mepolizumab therapy, identified significant associations with multiple viral related pathways e.g. viral infection, release of lentivirus. Other significant associations were related to inflammatory diseases such as psoriasis and immune related inflammatory disease. A full list of disease associations is provided (Supplement Table 2).

### **Mepolizumab-induced changes in gene expression are associated with inflammation, xenobiotic metabolism and fibrosis pathways**

Pathway analysis of the gene expression changes following Mepolizumab therapy show evidence of suppression of inflammatory pathways. For example, pathways related to crosstalk between dendritic cells and natural killer cells, “type 1 diabetes and interferon signalling were observed. There is also evidence of activation of fibrotic pathways e.g. FGF signalling, epithelial mesenchymal transition and pulmonary fibrosis idiopathic signalling pathways (Figure 2D). Full pathway analysis is provided (Supplement Table 3).

### **Mepolizumab-induced changes in gene expression are associated with upstream cytokine activity**

Upstream analysis is used to identify regulators that may be responsible for the observed gene expression changes. Mepolizumab-induced changes in gene expression were identified to, at least in part, be due to activity changes in asthma related cytokines such as IL13, IFN-alpha, IL1-beta and TNF-alpha (Figure 3A, orange circles) and transcription regulators, for example SP1 and STAT1 (blue circles). Full upstream regulator analysis is provided (Supplement Table 4).

### **Mepolizumab-induced changes in gene expression are associated with a decrease in downstream neutrophil activation**

Downstream functional effects analysis is used to identify functional pathways expected to be activated or inhibited, given the observed expression in the dataset. Mepolizumab-induced gene expression changes show a significant association with an inhibition of activation of peripheral blood neutrophils pathways (z-score of -2.9, Figure 3B). A general activation in gene expression (Figure 3B, red circles) and cellular assembly pathways (green circles) is also observed. Full downstream functional effects analysis is provided (Supplement Table 5).

### **There are significant differences in gene expression between responders and non-responders after Mepolizumab therapy**

Differential analysis between baseline and post-Mepolizumab treatment gene expression in the responder group alone resulted in 1142 down regulated and 2145 up-regulated genes (adjusted p-value <0.05) (Figure 4A), while 1012 down-regulated and 1382 up-regulated genes were identified in the non-responder group alone (adjusted p-value <0.05) (Figure 4B). Of these, 1784 genes were unique to responders alone and 893 genes were unique to non-responders alone, with the remaining 1500 genes (36%) overlapping (Figure 4C). However, some caution should be used in interpretation due to the differences in responder (n=17)/non-responder (n=10) group sample size. At baseline we found no significant differences in gene expression between responders and non-responders. A list of unique differentially expressed genes for the separate responder or non-responder groups is provided (Supplement Tables 6 and 7).

### **Mepolizumab-induced gene expression changes are associated with downstream respiratory disease in non-responders but not responders**

Disease association pathway analysis of separate responder and non-responder Mepolizumab-induced changes in gene expression, commonly tagged broad terms such as fibrosis, viral infection, immune mediated inflammatory disease and eosinophilia. A large group of specific respiratory and auto-immune disease associations were only present in the non-responder group (Figure 4D). Full disease analysis is provided (Supplement Table 8).

### **Mepolizumab-induced changes in gene expression are associated with upstream cytokine activity in non-responders**

Upstream regulator analysis in separate responder and non-responder groups showed an overlap of 170 regulators (adjusted p-value <0.05). Mepolizumab-induced gene expression changes were associated with an activation of upstream regulators of TSLP, IL4 and IL33 cytokines in the non-responder dataset only (Figure 5A, orange circles) suggesting there is ongoing T2 inflammation in the airways. Full upstream regulator analysis is provided (Supplement Table 9).

## **Mepolizumab-induced changes in gene expression are associated with a decrease in downstream neutrophil activation in responders but not non-responders**

Mepolizumab induced gene expression changes drove different downstream pathways in responder and non-responder datasets. A responder signature included suppression of pathways related to activation of peripheral blood neutrophils, quantity of superoxide, apoptosis and cell death of epithelial cells and increases pathways related to intracellular assembly pathways including; microtubule dynamics, organization of cytoplasm and cytoskeleton (Figure 5B, triangles). In the non-responder dataset, there was an inhibition in pathways related to cellular homeostasis, adhesion of immune cells, cell survival viability. Pathways related to cell death of immune cells and fibroblast development were modestly activated (Figure 5B, circles). Full downstream functional effects analysis is provided (Supplement Table 10).

## **Mepolizumab treatment induces changes in DNA methylation in the nasal epithelium**

Principal component analysis (Figure 6A) of DNA methylation did not show any distinct clustering of patients post-Mepolizumab therapy (red dots) compared to baseline (blue dots) in contrast to the gene expression data. A total of 53 CpG sites were differentially methylated (FDR  $p < 0.05$ ) after 3 months of Mepolizumab treatment (Figure 6B). Methylation values of these sites in each patient sample show the changes in DNA methylation after therapy (Figure 6C). Full list of differentially methylated CpG sites is provided (Supplement Table 11).

## **Genes which correlate with Mepolizumab-induced changes in DNA methylation are associated with primary ciliary dyskinesia, cellular assembly, movement and metabolism**

There were 1452 significant DNA methylation and gene expression correlations. This involved 42 (79%) of the differential methylated sites and 838 (12%) of differentially expressed genes (Figure 7A and B). Disease pathway analysis showed a strong association with respiratory diseases such as primary ciliary dyskinesia, chronic familial respiratory disorder and sinus disorder (Figure 7C). Full correlation and disease analyses is provided (Supplement Tables 12 and 13).

Downstream function analysis of correlated genes show association with pathways predominantly involved in cell movement, migration of cells, organisation of the cytoplasm and metabolism of reactive oxygen species (Figure 7D). Full downstream functional effects analysis is provided (Supplement Table 14).

No significant changes in DNA methylation were seen when comparing responder and non-responder methylation profiles at baseline or when comparing baseline and post-Mepolizumab therapy DNA methylation in responder or non-responder datasets separately.

## Discussion

This study set out to identify changes in gene expression and/or DNA methylation in response to Mepolizumab in the nasal epithelium in patients with severe asthma to provide novel understanding of drug mechanisms, and to test the hypothesis that there may be an identifiable gene signature present at three months that predicts clinical response at one year. Overall, these data suggest that 3 months of Mepolizumab treatment significantly impacts airway epithelial gene expression and, by inference, homeostasis in severe asthma, leading to a potentially more homogeneous profile than at recruitment. Of note, there was a suppression of inflammation pathways, particularly those related to viruses/interferons. Interestingly, when gene expression analyses were completed separately in responders/non-responders, distinct gene expression profiles were identified. Non-responders exhibited, amongst others, elevated upstream activation of IL33, TSLP and IL4, suggesting ongoing T2 inflammation remains following treatment, furthermore, respiratory disease associations also remain. In contrast, in responders, gene expression associated with a decrease in downstream neutrophil activation was a feature. Finally, we also investigated the effect of Mepolizumab on DNA methylation and illustrate that a large proportion of differential methylation post treatment is associated with gene expression differences demonstrating that methylation at least in part contributes to the mechanisms driving altered gene expression. In post-Mepolizumab samples *TET3* also showed a slight but significant increase in expression (logFC 0.25) indicating Mepolizumab may be altering DNA methylation mechanisms. These novel data provide a unique insight into the impact of Mepolizumab in the airway epithelium and highlight potential signatures found in the clinical responder population.

To our knowledge, this is the first study to investigate gene expression and DNA methylation in the nasal epithelium of severe adult asthma patients in response to Mepolizumab treatment. Mepolizumab has previously been shown to induce elevated tight junction formation and cilium organisational genes in nasal scrapings from aspirin exacerbated respiratory disease patients (10), which we have also observed in our own results, especially those correlated with DNA methylation. In this study, we show that Mepolizumab has a broad effect on nasal epithelial gene expression, providing new insight and potentially confirming the hypothesis that there is an anti-inflammatory effect on the airway epithelium. This anti-inflammatory property is driven not only by the observation that several chemokine genes were suppressed, including CXCL5, 10 and 11, all known to be important in asthma, but also through more novel findings, e.g. changes in pathways related to fibrosis.

When looking at Mepolizumab-induced gene changes in all asthma patients, cytokines such as IL13, and IL1RN are activated in pathways predicted to explain these gene expression changes, whereas IFN-alpha and -gamma, IL1-alpha and -beta, IL17A, and TNF-alpha are predicted to be inhibited. Other studies have also shown cytokines to be affected by Mepolizumab therapy. One study found IL1 receptor antagonist to be increased after 4 weeks of Mepolizumab therapy (11) whereas in another study serum levels of TSLP were reduced after Mepolizumab therapy (12).

The current study has taken a molecular approach in investigating a response signature. Other studies have focussed on genetic associations (13), blood (14) or sputum biomarkers (15), clinical features such as lung function (16) or even characterising super responders (17) but



have found limited evidence. However, ACQ scores have been shown to be predictors of response (18).

Explorative analysis into specific responder or non-responder groups alone, shows that, IL4, IL33, and TSLP are activated and IL1-alpha and -beta and IFN-alpha 2 are inhibited in non-responders only. These results indicate that overall non-responders are experiencing a higher degree of inflammation that is both epithelial and inflammatory cell driven. Furthermore, inhibition of IL-1 and IFN activities could indicate inadequate responses to infections and therefore poor outcome (19). This complexity of the cytokine environment requires further investigation and may in part explain differences in responses and may advocate for alternative methods of treatment. Therapies aimed at targeting the upstream epithelial alarmins such as TSLP (Tezepelumab) and IL33 (Itepekimab) may provide an alternative or dual therapy for patients who do not respond to Mepolizumab (20).

Another gene in our study, CCL5, was found to be unique to responders and had a slight decrease in activity (logFC -0.56). This is of particular note as it is a chemoattractant for eosinophils (21). Another chemoattractant CCL4 has been shown to be lower in the blood of responders compared to non-responders at baseline and after 4 weeks of Mepolizumab therapy (22).

As well as cytokines, investigation of alternate immune cells such as neutrophils may also benefit those patients who do not respond to Mepolizumab. Although we did not see a change in neutrophil numbers in the blood post-treatment (data not shown), at the molecular level, Mepolizumab-induced changes in gene expression were associated with a downstream suppression of the neutrophil activation pathway only in patients who responded to treatment. This may provide an additional mechanism of action of Mepolizumab. In a recent study in asthma patients challenged with rhinovirus, Mepolizumab prevented an increase neutrophil numbers and activation in sputum (23). Similarly, in a study of nasal lavage gene expression, a module of genes related to neutrophil chemotaxis, was found to be inversely associated with exacerbations (24).

In the same nasal lavage study, increased expression of epithelium related gene modules was observed after 52 weeks of Mepolizumab therapy and associated with exacerbation (24). Structural, cellular and tissue changes, such as fibrotic pathways, were also associated with Mepolizumab induced gene expression changes in our study, indicating that Mepolizumab may affect cellular structure and possibly airway remodelling. Although there are no current studies that have directly investigated the role of Mepolizumab in airway remodelling, a study looking at Lebrikizumab, which neutralises IL13, suggests it may reduce asthmatic airway remodelling (25). Interestingly these structural cell biology mechanisms are also strongly correlated with changes in DNA methylation. Previous studies have shown differentially methylated regions to be associated with asthma and relevant genes such as IL4 and IL13 (26). DNA methylation changes have also been associated with cytoskeletal remodelling in asthma (27). Collectively these data and our study suggest cellular structural changes and airway remodelling is a key mechanism that needs to be explored further.

This is the first time the effect of Mepolizumab on gene expression and DNA methylation in the nasal epithelium of patients with severe asthma has been studied. We have found that Mepolizumab affects the inflammatory profile, neutrophil activation, and cellular structural mechanisms in the upper airway epithelium. From our explorative responder/non-responder

analysis, our data suggests that there may be an early gene expression signature to indicate response, predominantly related to a reduction in the T2 inflammatory profile in responders but a sustained T2 inflammatory profile in non-responders. However, due to the differences in sample size and therefore statistical power between the responder and non-responder groups, these results need to be interpreted with caution and replication would be of benefit to add confidence to the results but to our knowledge there is no replication cohort with nasal brush samples for which this can be done at the moment. Finally, we have found that changes in DNA methylation associate with gene expression and these are related to cellular assembly, metabolism and movement. Taken together, our data has provided novel molecular insight into the effect of Mepolizumab therapy in severe asthmatic patients and provides a basis for further investigation into molecular mechanisms of response that may lead to a more tailored approach to prescribing.

### **Data sharing**

The RNA sequencing and DNA methylation data will be deposited in a publicly available database upon acceptance for publication. Summary data is available in the supplements.

### **Declaration of interests**

None.

### **Acknowledgements**

Mohammed Ali for his help in administration, recruitment and sample processing. Laura Matthews, Helen Bailey, Carly Clayton, Karina Bingham, and Rebecca M Cooper for their help in sample acquisition and processing.

### **References**

1. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204-22.
2. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. *J Allergy Clin Immunol*. 2015;135(4):896-902.
3. Casale TB, Burnette A, Bourdin A, Howarth P, Hahn B, Stach-Klysh A, et al. Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies. *Thorax*. 2022;16:17534666221107313.
4. Fainardi V, Pisi G, Chetta A. Mepolizumab in the treatment of severe eosinophilic asthma. *Immunotherapy*. 2016;8(1):27-34.
5. Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. *Respir Res*. 2019;20(1):179.
6. Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. *Eur Respir J*. 2020;56(4).

7. Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al. A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED. *Am J Respir Crit Care Med*. 2017;195(4):443-55.
8. Pandey G, Pandey OP, Rogers AJ, Ahsen ME, Hoffman GE, Raby BA, et al. A Nasal Brush-based Classifier of Asthma Identified by Machine Learning Analysis of Nasal RNA Sequence Data. *Sci Rep*. 2018;8(1):8826.
9. Jackson DJ, Busby J, Pfeffer PE, Menzies-Gow A, Brown T, Gore R, et al. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. *Thorax*. 2021;76(3):220-7.
10. Buchheit KM, Lewis E, Gakpo D, Hacker J, Sohail A, Taliaferro F, et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol*. 2021;148(2):574-84.
11. Nowak-Jurek A, Gajewski A, Frachowicz-Guereirro K, Antczak-Marczak M, Gulbas I, Kowalski ML, et al. Cytokines in serum, nasal secretion and exhaled breath condensate during mepolizumab therapy in patients with different phenotypes of severe eosinophilic asthma: A pilot study. *Clin Exp Allergy*. 2022.
12. Kalinauskaite-Zukauske V, Januskevicius A, Janulaityte I, Miliauskas S, Malakauskas K. Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report. *Can Respir J*. 2019;2019:8607657.
13. Condreay L, Chiano M, Ortega H, Buchan N, Harris E, Bleecker ER, et al. No genetic association detected with mepolizumab efficacy in severe asthma. *Respir Med*. 2017;132:178-80.
14. Landi C, Vantaggiato L, Shaba E, Cameli P, Carleo A, d'Alessandro M, et al. Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment. *Pulm Pharmacol Ther*. 2021;70:102060.
15. Pavord ID, Buhl R, Kraft M, Prazma CM, Price RG, Howarth PH, et al. Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab. *ERJ Open Res*. 2022;8(2).
16. Lemiere C, Taille C, Lee JK, Smith SG, Mallett S, Albers FC, et al. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials. *Respir Res*. 2021;22(1):184.
17. Atayik E, Aytakin G. A Single Center Experience of Super-Responders Among Severe Asthma Patients Receiving Treatment with Mepolizumab. *Turk Thorac J*. 2022;23(5):348-54.
18. Eley L, Pantin T, Holmes LJ, Tavernier G, Fowler SJ. Outcomes over the first two years of treatment with mepolizumab in severe asthma. *Eur Respir J*. 2021;58(6).
19. Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [III]: agents targeting interleukins, immunoglobulins and complement factors). *Clin Microbiol Infect*. 2018;24 Suppl 2:S21-S40.
20. Tamari M, Trier AM, Kim BS. Emerging targeted therapeutics underscore immunologic heterogeneity of asthma. *J Allergy Clin Immunol*. 2021;148(3):719-21.
21. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. *J Exp Med*. 1992;176(2):587-92.
22. Suzukawa M, Ohshima N, Tashimo H, Asari I, Kobayashi N, Shoji S, et al. A Low Serum CCL4/MIP-1beta Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab. *Intern Med*. 2020;59(22):2849-55.
23. Sabogal Pineros YS, Bal SM, van de Pol MA, Dierdorp BS, Dekker T, Dijkhuis A, et al. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study. *Am J Respir Crit Care Med*. 2019;199(4):508-17.

24. Jackson DJ, Bacharier LB, Gergen PJ, Gagalis L, Calatroni A, Wellford S, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet*. 2022;400(10351):502-11.
25. Austin CD, Gonzalez Edick M, Ferrando RE, Solon M, Baca M, Mesh K, et al. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). *Clin Exp Allergy*. 2020;50(12):1342-51.
26. Legaki E, Arsenis C, Taka S, Papadopoulos NG. DNA methylation biomarkers in asthma and rhinitis: Are we there yet? *Clin Transl Allergy*. 2022;12(3):e12131.
27. Wawrzyniak P, Krawczyk K, Acharya S, Tan G, Wawrzyniak M, Karouzakis E, et al. Inhibition of CpG methylation improves the barrier integrity of bronchial epithelial cells in asthma. *Allergy*. 2021;76(6):1864-8.

Table 1. Clinical and demographic features of patients at baseline and/or 12-months (as indicated) and comparison between responder and non-responder groups.

	All patients	Non-responder (n=10)	Responder (n=17)	P value
Sex / Female no. (%)	17 (62.1)	8 (80)	9 (52.9)	0.16†
Age / years (IQR)	57.38 (38.40, 65.27)	58.55 (44.58, 68.96)	57.38 (38.24, 64.58)	0.55‡
Body mass index (SD)	32.62 (7.35)	32.59 (9.33)	32.83 (6.17)	0.94§
Comorbidity* / yes (%)	24 (89.7)	9 (90)	15 (88.2)	0.89†
Atopic Rhinitis (%)	2 (7.4)	1 (10)	1 (5.9)	0.693†
Smoking never/ex/current (%)	13 (44.8) / 13 (44.8) / 3 (10.3)	6 (60) / 3 (30) / 1 (10)	6 (35.3) / 10 (58.8) / 1 (5.9)	0.35†
Asthma control questionnaire / average score of 6 (SD)	3.28 (1.42)	3.42 (1.62)	3.27 (1.42)	0.81§
Exacerbations / year pre-recruitment (SD)	6.32 (3.19)	5.78 (3.23)	5.82 (2.40)	0.97§
Exacerbations / year 12-months post recruitment (SD)	2.67 (2.50)	5.14 (2.91)	1.64 (1.41)	0.02§
OCS at baseline - prednisolone dose/mg (SD)	11.78 (12.85)	16.80 (17.73)	8.82 (8.15)	0.121§
OCS at 12 months – prednisolone dose/mg (SD)	8.36 (12.01)	20.00 (18.71)	4 (3.27)	0.003§
FEV <sub>1</sub> % predicted (SD)	67.64 (22.47)	58.65 (21.53)	69.79 (51.52)	0.24§
FEV <sub>1</sub> /FVC (SD)	68.22 (12.24)	65.83 (12.71)	68.64 (12.79)	0.61§
Eosinophils highest in year pre-recruitment / $\times 10^9/L$ (IQR)	0.55 (0.40, 0.71)	0.5 (0.37, 0.72)	0.50 (0.40, 0.70)	0.51‡
White blood cells (IQR)	8.00 (6.66, 9.66)	8.53 (6.85, 9.29)	7.70 (6.36, 10.78)	0.74‡

\*Comorbidities defined as anxiety/depression, cancer, deep vein thrombosis, diabetes, eczema, hay fever, hypertension, ischaemic heart disease, pulmonary embolism, reflux or renal failure

†Chi-Square Test, ‡Mann-Whitney U Test, §Independent T-Test,

### **Figure 1. Study design and analysis workflow for gene expression and DNA methylation data.**

(A) Patients were recruited into the PROCLAIM study and nasal brush samples were taken at baseline and 3 months post-Mepolizumab therapy. DNA and RNA was extracted from the same brush. Gene expression was analysed through polyA RNA sequencing and DNA methylation through the EPIC Array. Gene expression and DNA methylation raw data was evaluated as part of quality control, filtered and normalised before differential analysis. (B) A differential analysis was conducted to compare gene expression and DNA methylation differences between baseline and post-Mepolizumab therapy in all paired samples and a pathway analysis was conducted on the differentially expressed genes. Differentially expressed genes and differentially methylated CpG sites were correlated, and a pathway analysis run on the correlated genes (C) A differential analysis was conducted to compare gene expression and DNA methylation differences between baseline and post-Mepolizumab therapy in either responder or non-responder paired samples alone and pathway analyses were conducted on the differentially expressed genes. An adjusted p value cut off of  $<0.05$  was applied for all data.

### **Figure 2. Mepolizumab induces gene expression changes in the nasal epithelium of severe asthma patients.**

(A) Principal component analysis shows clustering of patients' gene expression after Mepolizumab therapy. (B) Volcano plot of baseline vs post-Mepolizumab differential gene expression in all subjects. (C) Heatmap of the differentially expressed genes grouped into baseline and post-Mepolizumab blocks. (D) Pathways associated with Mepolizumab-induced gene expression changes. An adjusted p value of  $<0.05$  was applied for all data.

### **Figure 3. Mepolizumab-induced gene expression changes are associated with cytokine activity.**

(A) A bubble plot of upstream regulator associations with Mepolizumab-induced gene expression. Upstream regulators are plotted according to p-value and z-score, with the size of the bubble indicating the number of genes in the dataset affected by the regulator. (B) A bubble plot of downstream functional pathway associations with Mepolizumab-induced gene expression. Pathways are plotted according to  $-\log(\text{p-value})$ , due to the broad range of p-values from the data, and z-score, with the size of the bubble indicating the number of genes in the dataset affected by the pathway. An adjusted p value of  $<0.05$  was applied for all data.

### **Figure 4. There are differences in gene expression between responders and non-responders at one year following 3 months of Mepolizumab treatment.**

(A) Volcano plot of baseline vs post-Mepolizumab differential gene expression in responders alone. (B) Volcano plot of baseline vs post-Mepolizumab differential gene expression in non-responders alone. (C) Venn diagram to show overlap of differentially expressed genes between responder and non-responder groups. (D) Disease associations from pathways

analysis in separate responder and non-responder groups. Diseases have been grouped into type. Diseases circled in yellow indicate associations common to both responder and non-responder groups. Purple rectangles indicate associations found in the non-responder group only. Due to a large number of disease associations only auto-immune, infectious, inflammatory, or respiratory diseases have been shown. There were no associations found in the responder group alone. An adjusted p value of  $<0.05$  was applied for all data.

**Figure 5. Specific differentially expressed genes post-Mepolizumab therapy are associated with an increase in upstream cytokine regulators in non-responders and an increase in intracellular assembly pathways in responders.**

(A) A bubble plot of upstream regulator associations which were unique to responders or non-responders (associations common to both groups not shown). Upstream regulators are plotted according to  $-\log(\text{p-value})$ , due to the broad range of p-values from the data, and z-score, with the size of the bubble indicating the number of genes in the dataset affected by the regulator. (B) A bubble plot of downstream functional pathway associations which were unique to responders or non-responders (associations common to both groups not shown). Pathways are plotted according to  $-\log(\text{p-value})$ , due to the broad range of p-values from the data, and z-score, with the size of the bubble indicating the number of genes in the dataset affected by the pathway. An adjusted p value of  $<0.05$  was applied for all data.

**Figure 6. Mepolizumab induces DNA methylation changes in the nasal epithelium of severe asthma patients.**

(A) Principal component analysis shows no clustering of patients' DNA methylation profiles after Mepolizumab therapy. (B) Volcano plot of baseline vs post-Mepolizumab differential DNA methylation. (C) Heatmap of the differentially methylated CpG sites grouped into baseline and post-Mepolizumab blocks. An adjusted p value of  $<0.05$  was applied for all data.

**Figure 7. Mepolizumab induced changes in gene expression and DNA methylation correlate with each other.**

(A) Representative correlations between 3 different genes and correlated CpG sites. Blue dots show samples at baseline and red dots show samples post-Mepolizumab therapy. (B) Plot of all CpG site and gene correlations. Each dot represents a correlation between a CpG site and gene. (C) Diseases associated with 838 differentially expressed genes which were correlated with 42 of the differentially methylated CpG. (D) Downstream functional pathways associated with these 838 genes. Pathways have been grouped into types and the number of genes in each pathway are in brackets. An adjusted p value of  $<0.05$  was applied for all data.

**A****Patient recruitment and sample processing**

- Patients recruited
- Nasal swabs taken at baseline (pre-Mepolizumab) and at 3 months of Mepolizumab treatment
- Nasal swab processed to cell pellet and stored at -80 °C

**DNA and RNA extraction using dual kit****RNA – gene expression**

- polyA RNA sequencing 25M reads
- Alignment to GRCh37.87 (STAR)
- Filtering and normalisation (edgeR)
- Differential gene expression (limma)

**DNA – methylation**

- EPIC array 850k CpG sites
- Normalisation, probe filtering and batch effect correction (funnorm, combat)
- Differential CpG site methylation (limma)

**B****All samples****Baseline vs Post-Mepolizumab**

27 baseline and 27 matched post-Mepolizumab samples for paired analysis

6719 differentially expressed genes and 53 differentially methylated CpG sites (adjusted  $p < 0.05$ )

Pathway analysis of differentially expressed genes

Correlation analysis of gene expression and DNA methylation

Pathway analysis of 838 correlated genes

**C**

**Responders only**

**Non-Responders only**

**Baseline vs Post-Mepolizumab**

17 Responder and 10 non-responder samples for paired analysis within each group.





3287 differentially expressed genes in responder group and 2394 in non-responder group (adjusted  $p < 0.05$ ). No differentially methylated CpG sites.

Venn diagram to identify unique and common genes


Pathway Analysis on differentially expressed genes for responders and non-responders

Identification of unique and common pathways/mechanisms/regulators.






**A**




**B**








**A**




1142 genes down-regulated, 2145 genes up-regulated





**B**

1012 genes down-regulated, 1382 genes up-regulated

**C****D**

**A****B**





## Supplement

### **Mepolizumab induced changes in nasal methylome and transcriptome to predict response in asthma**

<sup>1,2</sup>Kamini Rakkar, <sup>1,3</sup>Yik Lam Pang, <sup>1,2</sup>Poojitha Rajasekar, <sup>1,2</sup>Michael A Portelli, <sup>1,2</sup>Robert J Hall, <sup>1,2</sup>Rachel L Clifford, <sup>1,3</sup>Dominick Shaw and <sup>1,2</sup>Ian Sayers

<sup>1</sup>Centre for Respiratory Research, National Institute for Health Research Nottingham, Biomedical Research Centre, School of Medicine, <sup>2</sup>Nottingham University Biodiscovery Institute & <sup>3</sup>Clinical Sciences Building, City Hospital, University of Nottingham, Nottingham, United Kingdom

Corresponding author

Kamini Rakkar

Biodiscovery Institute, Science Road, University of Nottingham, NG7 2RD

kamini.rakkar2@nottingham.ac.uk

## Methods

### Recruitment

The PROCLAIM study (Poor Response to monoClonal therapy In asthMa) recruited 42 patients with severe asthma who matched the National Health Service (NHS) criteria for receiving Mepolizumab (TA431) between January 2019 and June 2020 (1). The study was approved by the Medical Ethics Committee (REC18/EM/0268).

### Inclusion criteria

All patients will be able to give informed consent for study participation

All patients identified as being suitable for anti-IL5 therapy by the regional severe asthma multidisciplinary team (MDT) at Nottingham Universities Hospitals NHS Trust was considered for study enrolment. This assessment by the MDT for participants to be eligible includes:

- Confirmation of asthma diagnosis
- Historic blood eosinophil counts,
- Annual asthma exacerbation rates
- Oral Prednisolone dose.
- Patients must demonstrate over 75% compliance with inhaled corticosteroid therapy
- The asthma MDT and difficult asthma clinic normally assess patients between 18-80 years so only patients in this age range will be approached
- Confirmation of treatment with anti-IL5 requires at least two asthma specialists to agree that this is the correct course of action

### Exclusion criteria

Pregnancy

### Sample collection

Nasal brushes were taken at baseline (pre-drug) and 3-months of Mepolizumab treatment and were immediately placed in 3 mL of cold PneumaCult-Ex cell culture media (Stemcell) and stored on ice until processing. Nasal brushes were vortexed and scraped to dislodge cells into the media. The brush was discarded, and the cell suspension centrifuged at 200g. The media supernatant was removed, and cell pellet stored at -80 °C until dual RNA/DNA Purification (Norgen Biotek Corp.). DNA was stored at -20 °C and RNA was stored at -80 °C until use.

### Responder group allocation

Responders were defined as patients who had a 50% reduction in oral corticoid steroid use or 50% reduction in exacerbation frequency after one year of Mepolizumab therapy.

### RNA sequencing

Gene expression was determined through stranded paired end polyA RNA sequencing (Oxford Genomics) using Illumina v1.5 chemistry and the NovaSeq6000 at a minimum of 25M reads. Raw data was aligned to the GRCh37 human assembly using STAR. All further data processing and analysis was undertaken with different packages in RStudio (2). Raw read counts were transformed to counts per million values, unexpressed transcripts removed, and the data normalised using edgeR (v3.38.1). Paired sample weighted differential gene expression, with epithelial cell proportions as calculated below, was determined using Limma (v3.52.1) (3).

### DNA methylation

DNA methylation was determined through the Illumina Infinium MethylationEPIC Bead Chip Array (Diagenode) which covers 850,000 methylation sites. Raw data was processed and analysed using packages in RStudio. Data was normalised using FunNorm (minfi v1.42.0). Probes with less than 3 beads, low detection p values, SNPs at CpG target sites and single base extension sites for type I probes, and which were cross reactive and XY chromosomes specific were removed (Figure 1) (4). Data was batch effect corrected for array and array position using ComBat (sva v3.44.0). The proportion of epithelial cells in each sample was



determined using EpiDISH (v2.12.0) (5) and differential CpG site methylation was determined using Limma (v3.52.1) (6).

### **Gene expression and DNA methylation correlation**

All differentially expressed genes and CpG sites from the baseline vs post-Mepolizumab analysis were correlated in RStudio using Limma (v3.52.1).

### **Pathway Analysis of gene expression**

The Ingenuity Pathway Analysis tool (Qiagen) was used to determine disease, pathway, upstream regulator, and downstream functional effect associations for identified gene lists. Whole gene expression datasets with adjusted p-values and log fold changes in gene expression were used. Where there was enough data available IPA also calculated Z-scores indicating whether the particular pathway had an increase (positive z-score) or decrease (negative z-score) in activity. For the correlated DNA methylation and gene expression dataset a gene list without numerical data was used as these correlations were not specific to a timepoint and therefore the matched gene expression data could not be used, consequently Z-scores and directionality of pathway associations were not determined. An adjusted p value of  $<0.05$  was applied for all associations and the whole dataset itself was used as the reference (7).


### **Statistical analyses**

Patient clinical and demographic data were analysed in SPSS (v28). Data were tested for normality using the Shapiro-Wilk test. Those with a normal distribution were analysed using the Independent Student's T-test. Data with non-normal distributions were analysed using a Mann Whitney U test. Categorical data were analysed using the Chi-Square Test of Independence. P values of  $<0.05$  were considered significant. For DNA methylation, data was analysed using linear modelling and empirical Bayes. For RNA sequencing, data was analysed using precision weighted linear modelling and empirical Bayes. For the DNA methylation and gene expression correlation a linear model was used. Adjusted p values (Benjamini-Hochberg correction) of  $<0.05$  were considered significant.


## References

1. Mepolizumab for treating severe refractory eosinophilic asthma, Technology appraisal guidance [TA431]. 2017.
2. Law CW, Alhamdoosh M, Su S, Dong X, Tian L, Smyth GK, et al. RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR. *F1000Res*. 2016;5.
3. Liu R, Holik AZ, Su S, Jansz N, Chen K, Leong HS, et al. Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses. *Nucleic Acids Res*. 2015;43(15):e97.
4. Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. *Epigenetics*. 2013;8(2):203-9.
5. Teschendorff AE, Breeze CE, Zheng SC, Beck S. A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies. *BMC Bioinformatics*. 2017;18(1):105.
6. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*. 2015;43(7):e47.
7. Kramer A, Green J, Pollard J, Jr., Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics*. 2014;30(4):523-30.

## Results



**Supplementary Figure 1. Number of probes removed at each stage of QC for the DNA methylation analysis.** After all QC steps 684,807 probes remained in the analysis.



**Supplementary Figure 2. Cell type composition based on DNA methylation data.** The EpiDISH package in R was used to determine the cell type composition of the nasal brush samples. Plots show proportion of each cell type for each sample in (A) all samples, and samples at (B) baseline and (C) post-Mepolizumab therapy stratified by visit or responder status. The box and whisker plots show the minimum, first quartile, median, third quartile, and maximum proportional values.

Supplementary Table 1. List of differentially expressed genes in baseline vs post-Mepolizumab therapy analysis in all patients. The top 50 most up/down regulated genes are shown.

Up-regulated

Down-regulated

SYMBOL	logFC	adj.P.Val
RP11-706O15.3	4.28	3.16E-09
LINC00689	3.78	3.60E-07
LHX6	3.64	2.80E-05
MEG3	3.54	5.56E-04
RIMBP3	3.24	3.27E-07
WSCD2	3.17	6.08E-08
FN1	3.07	9.15E-05
MDGA1	3.06	1.68E-07
DOK6	3.05	1.64E-05
NPBWR1	3.00	3.64E-06
ISLR	2.88	1.66E-06
LINC01060	2.85	1.09E-07
NXF2B	2.80	5.32E-07
SMOC2	2.69	7.13E-06
NUDT10	2.60	1.82E-07
ELFN1	2.47	6.36E-05
SCN2B	2.43	2.20E-04
COL6A1	2.42	2.18E-10
RP11-439A17.7	2.40	4.44E-06
FMOD	2.40	7.68E-07
CDHR1	2.39	1.91E-04
LYPD1	2.38	6.70E-06
SPATA22	2.37	6.62E-05
NTF3	2.36	2.91E-07
AC024560.2	2.36	1.92E-05
TRO	2.36	2.83E-07
FAM230B	2.34	3.48E-06
FAM41C	2.29	1.33E-03
TOX	2.27	2.35E-07
NUTM2E	2.27	1.84E-05
AC023490.1	2.27	8.09E-04
DKK3	2.26	8.64E-06
DDTL	2.26	3.48E-05
OXTR	2.26	9.26E-05
LOC440461	2.25	1.39E-04
FAM69B	2.23	5.14E-06
MLXIPL	2.22	3.92E-05
NGB	2.20	1.05E-05
SCN4B	2.19	2.49E-05
GOLGA6L9	2.18	1.99E-03
PTGFR	2.18	1.42E-06
KCNJ1	2.16	4.79E-04
RP11-401E5.2	2.16	1.87E-07
FAM230C	2.13	9.15E-05
ZSCAN23	2.13	5.63E-05
METTL21EP	2.12	2.88E-09
GPX1P1	2.12	9.36E-06
POSTN	2.10	6.10E-05
TRIM63	2.08	3.12E-04
RP11-365O16.1	2.08	1.11E-03

SYMBOL	logFC	adj.P.Val
RP11-707O23.5	-3.64	6.19E-05
GSTM1	-3.59	2.49E-04
FCGBP	-3.45	1.07E-06
CXCL9	-3.39	5.45E-06
HLA-DQA2	-3.34	2.85E-06
DMBT1	-3.33	7.93E-07
CSF3	-3.23	3.71E-06
CXCL10	-3.10	3.68E-05
FOXL1	-3.01	3.28E-07
IRX4	-2.97	2.42E-06
HBA2	-2.94	6.85E-04
FOXC2	-2.78	7.87E-05
IRX1	-2.74	4.55E-05
CCL20	-2.73	3.16E-09
LDHC	-2.69	1.07E-07
PSPHP1	-2.68	1.45E-04
SFRP2	-2.67	1.79E-06
LRRC55	-2.63	1.77E-07
IRX2	-2.60	2.30E-07
UGT2B17	-2.58	2.60E-05
RPLP0P2	-2.52	1.91E-08
SERPINA3	-2.50	1.64E-05
PSG5	-2.48	2.90E-07
CXCL11	-2.41	5.72E-05
ADAM12	-2.37	6.31E-08
SLC46A2	-2.35	5.57E-07
C5orf38	-2.34	2.28E-05
RP11-747H12.6	-2.34	5.93E-05
IL17C	-2.34	2.06E-06
CHRNA3	-2.30	4.19E-05
HBA1	-2.29	3.30E-03
RP11-93B14.5	-2.28	1.01E-04
CLDN2	-2.22	5.39E-06
STXBP5L	-2.22	4.97E-05
GLYATL2	-2.21	4.67E-07
C3orf36	-2.19	1.96E-05
RP11-1399P15.1	-2.18	2.79E-05
SLC5A5	-2.18	3.16E-09
AL121901.1	-2.16	4.70E-05
FAM21B	-2.14	4.18E-04
CPNE4	-2.14	3.36E-06
MUC6	-2.13	9.04E-04
CTA-384D8.34	-2.13	2.20E-07
HLA-DQA1	-2.13	8.43E-08
SCGB3A1	-2.12	3.36E-04
HLA-DQB1	-2.11	1.20E-05
HBB	-2.08	9.15E-03
SLC26A4	-2.06	3.27E-06
RP11-497H16.6	-2.04	5.03E-05
TBX3	-2.04	9.23E-05

Supplementary Table 2. List of disease associations from differential gene expression analysis between baseline vs post-Mepolizumab therapy in all patients\*.

Diseases Annotation	P-value	Genes
Benign pelvic disease	2.79E-06	439
Dementia syndrome	6.76E-06	17
Lymphoproliferative disorder	6.78E-06	1287
MELAS syndrome	1.28E-05	15
Familial neurological disorder	1.34E-05	1034
Congenital neurological disorder	2.24E-05	415
Benign uterine disease	2.63E-05	300
Psoriasis	4.66E-05	264
Lethal skeletal dysplasia	5.61E-05	30
Liver lesion	8.62E-05	2439
Short-rib thoracic dysplasia	1.07E-04	23
Renal lesion	1.08E-04	780
Congenital encephalopathy	2.05E-04	269
Familial dementia	2.11E-04	45
Lichen planus	2.63E-04	48
Abnormality of endometrium	3.73E-04	2181
Autosomal domiNDt cleft lip with or without cleft palate	3.79E-04	7
Hutchinson-Gilford progeria syndrome	4.33E-04	95
Progressive encephalopathy	4.87E-04	431
Congenital anomaly of mouth	4.90E-04	94
Premature aging	5.20E-04	101
Familial encephalopathy	5.61E-04	778
Abnormal growth in endometrium	6.57E-04	2118
Metabolism of N-acetylglucosamine	7.87E-04	8
Skin lesion	7.96E-04	3622
Oral lesion	8.86E-04	596
Hereditary connective tissue disorder	8.88E-04	378
Orofacial dysmorphism	9.02E-04	92
Pancreatic lesion	9.61E-04	1311
Congenital hypopituitarism	1.00E-03	26
Microangiopathy	1.01E-03	94
Progressive neurological disorder	1.01E-03	502
Polydactyly	1.08E-03	22
Congenital hypogonadotropic hypogonadism	1.09E-03	17
Kallmann syndrome	1.19E-03	16
Benign oral disorder	1.26E-03	217
Viral Infection	1.28E-03	467
Glomerulosclerosis	1.31E-03	24
Hirschsprung disease 1	1.38E-03	20
Neurocristopathy syndrome	1.43E-03	57
COVID-19	1.53E-03	204
Olfaction disorder	1.74E-03	18
Congenital malformation of face	1.85E-03	86
Familial congenital malformation	1.92E-03	691
Congenital anomaly of gastrointestinal tract	1.93E-03	97
Hereditary skeletal myopathy	2.03E-03	158
Amyloidosis	2.10E-03	284
Infection by coronavirus	2.15E-03	206
Transient infantile mitochondrial myopathy	2.17E-03	7
Autism spectrum disorder or intellectual disability	2.22E-03	428
Hereditary neuropathy	2.29E-03	158
Hydronephrosis	2.39E-03	15
Focal segmental glomerulosclerosis	2.55E-03	19
Congenital anomaly of digit	2.81E-03	52
Familial nonsyndromic hearing impairment	2.81E-03	52
Infantile cytochrome C oxidase deficiency	2.81E-03	8

Jaundice	2.81E-03	8
Intracranial lesion	2.97E-03	3017
Brain lesion	3.12E-03	3023
Short rib thoracic dysplasia type 6 with polydactyly	3.13E-03	9
Release of lentivirus	3.18E-03	11
Hereditary myopathy	3.27E-03	316
Anosmia	3.29E-03	17
Nonsyndromic hearing impairment	3.34E-03	54
Immune mediated inflammatory disease	3.39E-03	590
Age-related macular degeneration	3.42E-03	28
Chronic granulomatous disease	3.51E-03	20
Bile duct hamartoma	3.60E-03	5
Helicobacter pylori-associated gastritis	3.60E-03	5
Lebers optic atrophy plus syndrome	3.60E-03	5
Recessive candidiasis	3.60E-03	5
Familial psychiatric disease	4.12E-03	419

\*Z-scores were determined for less than 5 disease associations by IPA and therefore have been omitted from the table.

Supplementary Table 3. Pathway analysis results from differential gene expression analysis between baseline vs post-Mepolizumab therapy in all patients\*.

Inguinity Canonical Pathways	-log(p-value)	Z-score	Genes
Antigen Presentation Pathway	6.33	ND	26
iNOS Signaling	4.41	-0.85	28
Neuroinflammation Signaling Pathway	3.65	-0.31	114
Xenobiotic Metabolism PXR Signaling Pathway	3.58	2.22	73
OX40 Signaling Pathway	3.56	0.91	29
Type I Diabetes Mellitus Signaling	3.25	-2.27	51
Role of IL-17A in Arthritis	3.24	ND	30
Glucocorticoid Receptor Signaling	3.04	ND	184
IL-17A Signaling in Fibroblasts	2.91	ND	21
Ethanol Degradation IV	2.85	1.39	13
Putrescine Degradation III	2.84	0.58	12
FGF Signaling	2.76	2.67	39
Dendritic Cell Maturation	2.70	-1.32	72
BAG2 Signaling Pathway	2.57	1.00	38
IL-17A Signaling in Airway Cells	2.44	0.41	32
Lysine Degradation II	2.44	2.24	5
Xenobiotic Metabolism Signaling	2.42	ND	103
Sirtuin Signaling Pathway	2.39	1.10	109
Notch Signaling	2.39	1.73	19
IL-17A Signaling in Gastric Cells	2.38	-0.33	15
MIF-mediated Glucocorticoid Regulation	2.33	-1.00	18
Regulation of the Epithelial-Mesenchymal Transition Pathway	2.28	ND	73
Pulmonary Fibrosis Idiopathic Signaling Pathway	2.27	5.09	119
Xenobiotic Metabolism AHR Signaling Pathway	2.26	2.26	35
Th2 Pathway	2.25	0.71	50
ILK Signaling	2.24	2.03	75
Hepatic Fibrosis Signaling Pathway	2.18	0.98	144
MIF Regulation of Innate Immunity	2.17	-0.23	21
Histamine Degradation	2.14	1.00	9
Crosstalk between Dendritic Cells and Natural Killer Cells	2.13	-2.13	31
B Cell Development	2.10	ND	14
Role of IL-17F in Allergic Inflammatory Airway Diseases	2.08	-0.26	22
TNFR2 Signaling	2.08	0.00	17
LPS/IL-1 Mediated Inhibition of RXR Function	2.02	-0.20	80
PCP (Planar Cell Polarity) Pathway	2.00	1.88	25
Acetate Conversion to Acetyl-CoA	1.95	0.00	4
Epithelial Adherens Junction Signaling	1.94	0.51	62
Regulation Of The Epithelial Mesenchymal Transition By Growth Factors Pathway	1.90	2.39	72
FAT10 Signaling Pathway	1.87	ND	25
LXR/RXR Activation	1.85	-1.51	40
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis	1.84	ND	110
Autophagy	1.82	-3.58	82
Tryptophan Degradation to 2-amino-3-carboxymuconate Semialdehyde	1.80	-1.34	5
Allograft Rejection Signaling	1.80	ND	20
Xenobiotic Metabolism CAR Signaling Pathway	1.77	2.50	64
Regulation Of The Epithelial Mesenchymal Transition In Development Pathway	1.72	2.41	33
Tryptophan Degradation X (Mammalian, via Tryptamine)	1.71	0.91	11
Ethanol Degradation II	1.71	1.60	14
PD-1, PD-L1 cancer immunotherapy pathway	1.68	0.85	40
Apelin Pancreas Signaling Pathway	1.67	0.47	20
Th1 and Th2 Activation Pathway	1.67	ND	58
Autoimmune Thyroid Disease Signaling	1.67	ND	20
ICOS-ICOSL Signaling in T Helper Cells	1.64	-1.18	45
Noradrenaline and Adrenaline Degradation	1.61	1.29	15
Chemokine Signaling	1.60	0.19	31
4-1BB Signaling in T Lymphocytes	1.60	0.30	17
T Cell Receptor Signaling	1.58	-1.10	69



RANK Signaling in Osteoclasts	1.57	0.54	38
PEDF Signaling	1.56	1.51	35
Serotonin Degradation	1.55	1.71	22
Interferon Signaling	1.53	-3.36	16
Coronavirus Replication Pathway	1.53	1.89	18
Docosahexaenoic Acid (DHA) Signaling	1.53	ND	18
Ferroptosis Signaling Pathway	1.50	-2.19	48
HER-2 Signaling in Breast Cancer	1.49	2.05	83
Serine Biosynthesis	1.47	ND	3
Thiosulfate Disproportionation III (Rhodanese)	1.47	ND	3
FAT10 Cancer Signaling Pathway	1.44	1.41	22
CD40 Signaling	1.42	1.23	28
Role of BRCA1 in DNA Damage Response	1.42	2.18	34
Mitochondrial Dysfunction	1.42	ND	63
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages	1.41	-1.13	69
Pulmonary Healing Signaling Pathway	1.41	1.81	69
Molecular Mechanisms of Cancer	1.41	ND	153
LPS-stimulated MAPK Signaling	1.40	-0.18	35
WNT/ $\beta$ -catenin Signaling	1.40	0.83	60
Dopamine Degradation	1.40	1.16	12
NF- $\kappa$ B Signaling	1.40	2.14	65
CMP-N-acetylneuraminate Biosynthesis I (Eukaryotes)	1.39	-2.00	4
Protein Kinase A Signaling	1.39	-0.40	131
IL-9 Signaling	1.39	0.83	16
Lysine Degradation V	1.39	2.00	4
Insulin Receptor Signaling	1.38	0.00	52
PPAR Signaling	1.37	1.00	40
Fatty Acid $\beta$ -oxidation	1.37	1.00	9
Tumor Microenvironment Pathway	1.36	1.92	63
Th1 Pathway	1.35	0.00	41
Reelin Signaling in Neurons	1.35	1.04	54
Endocannabinoid Cancer Inhibition Pathway	1.34	-2.77	55
Amyloid Processing	1.34	1.16	22
Graft-versus-Host Disease Signaling	1.31	ND	20
DNA Double-Strand Break Repair by Homologous Recombination	1.30	ND	8

\*Not determined (ND) indicates pathways for which no activity prediction can be made, even though genes are significantly associated with that pathway.

Supplementary Table 4. Upstream regulator analysis results from differential gene expression analysis comparing baseline vs post-Mepolizumab therapy in all patients\*.

Upstream Regulator	Molecule Type	Z-score	P-value	Genes
TNF-alpha	cytokine	-4.381	2.13E-09	188
LONP1	peptidase	-2.535	1.10E-04	14
MT-TE	other	ND	3.91E-04	7
NEUROG1	transcription regulator	0.186	4.75E-04	29
ERK1/2	group	0.816	5.50E-04	39
Interferon alpha	group	-3.257	1.05E-03	72
mir-183	microRNA	-0.795	1.14E-03	9
IL1RAP	transmembrane receptor	-0.816	1.20E-03	6
IFNG	cytokine	-4.711	1.52E-03	89
IL13	cytokine	1.626	1.71E-03	79
IL1A	cytokine	-2.597	2.15E-03	34
PELP1	other	ND	2.15E-03	34
TGFB1	growth factor	1.341	2.42E-03	85
TLR3	transmembrane receptor	-1.886	2.48E-03	33
TP63	transcription regulator	1.202	2.83E-03	95
APP	other	-1.56	2.98E-03	13
BRD4	kinase	1.964	3.21E-03	24
IL1B	cytokine	-1.75	3.33E-03	69
VBP1	other	-2.236	3.69E-03	5
ERVW-1	other	-0.246	3.69E-03	5
SLC9A3R1	transporter	0.555	3.69E-03	5
CG	complex	-1.43	3.70E-03	77
TGFBR2	kinase	ND	3.83E-03	30
MYC	transcription regulator	1.782	3.88E-03	38
TREM1	transmembrane receptor	-0.928	4.25E-03	67
MRTFB	transcription regulator	2.967	5.21E-03	30
TREX1	enzyme	5.161	5.48E-03	41
RELA	transcription regulator	-0.276	6.49E-03	38
IL17F	cytokine	-1.443	7.22E-03	7
mir-182	microRNA	0.478	7.22E-03	7
TSLP	cytokine	0.671	7.31E-03	15
NFKB1	transcription regulator	-0.037	8.06E-03	27
IL17A	cytokine	-2.691	8.08E-03	29
AURK	group	-1.225	9.19E-03	24
ANLN	other	-1.225	9.19E-03	24
TEAD4	transcription regulator	1.506	9.19E-03	24
NFkB (complex)	complex	-3.682	9.50E-03	42
IL1RN	cytokine	3.499	1.05E-02	31
CXCL8	cytokine	-0.098	1.07E-02	23
LATS2	kinase	-0.093	1.07E-02	12
CXCL12	cytokine	-0.814	1.08E-02	25
IL36A	cytokine	-2	1.13E-02	4
MAP2K3	kinase	-2	1.13E-02	4
MAP2K6	kinase	-1.995	1.13E-02	4
RFXANK	transcription regulator	ND	1.13E-02	4
IL1RL2	transmembrane receptor	-2	1.13E-02	4
STAT1	transcription regulator	-4.537	1.14E-02	39
LATS1	kinase	-0.389	1.21E-02	11
GATA4	transcription regulator	1.881	1.24E-02	22
P38 MAPK	group	-1.657	1.27E-02	43
FOXC1	transcription regulator	-4.229	1.34E-02	41
BTK	kinase	-3.499	1.51E-02	16
NONO	transcription regulator	-4.609	1.54E-02	49
mir-23	microRNA	-1.412	1.61E-02	5
MALSU1	other	-2.236	1.61E-02	5
TEAD3	transcription regulator	1.627	1.67E-02	20
TLR7	transmembrane receptor	-2.748	1.67E-02	20

WNT5A	cytokine	-2.326	1.72E-02	31
miR-218-5p (and other miRNAs w/seed UGUGCUU)	mature microRNA	-0.273	1.73E-02	7
mir-223	microRNA	-1.147	1.73E-02	7
NR3C2	ligand-dependent nuclear receptor	ND	1.75E-02	6
miR-2392 (miRNAs w/seed AGGAUGG)	mature microRNA	2.441	1.75E-02	6
mir-2392	microRNA	2.439	1.75E-02	6
RNASEH2B	other	5.098	1.84E-02	37
MUC1	other	0.347	2.03E-02	11
HEIH	other	1.678	2.03E-02	14
HNF1A-AS1	other	2.137	2.03E-02	11
PRL	cytokine	-2.107	2.06E-02	33
CLOCK	transcription regulator	-0.447	2.22E-02	46
IL33	cytokine	-0.207	2.26E-02	18
IRF1	transcription regulator	-1.342	2.33E-02	10
GRN	growth factor	-1.462	2.55E-02	33
OSCAR	other	-1.807	2.55E-02	15
TEAD2	transcription regulator	2.065	2.65E-02	19
GSK3B	kinase	-1.528	2.67E-02	9
PGR	ligand-dependent nuclear receptor	1.269	2.67E-02	9
PPP2R5C	other	2.333	2.67E-02	9
RNA polymerase II	complex	ND	2.75E-02	12
TEAD1	transcription regulator	1.506	2.96E-02	22
TLR9	transmembrane receptor	-3.446	2.96E-02	22
MDM4	transcription regulator	0.726	3.04E-02	8
ATF4	transcription regulator	1.134	3.04E-02	8
Nr1h	group	0.708	3.20E-02	11
TCR	complex	-0.813	3.33E-02	79
ILF3	transcription regulator	0.232	3.33E-02	31
Histone h4	group	ND	3.43E-02	7
miR-23a-3p (and other miRNAs w/seed UCACAUU)	mature microRNA	0.316	3.43E-02	7
LINC00963	other	-1.134	3.43E-02	7
SPARC	other	-0.503	3.43E-02	7
PROX1	transcription regulator	0.728	3.43E-02	7
CREBBP	transcription regulator	ND	3.43E-02	7
IKK (complex)	complex	ND	3.47E-02	3
GALNT6	enzyme	ND	3.47E-02	3
TGM2	enzyme	ND	3.47E-02	3
CTBP1	enzyme	ND	3.47E-02	3
EPRS1	enzyme	ND	3.47E-02	3
SMO	G-protein coupled receptor	ND	3.47E-02	3
Tnf receptor	group	ND	3.47E-02	3
MAP2K7	kinase	ND	3.47E-02	3
miR-516a-3p (and other miRNAs w/seed GCUUCCU)	mature microRNA	ND	3.47E-02	3
miR-101-3p (and other miRNAs w/seed ACAGUAC)	mature microRNA	ND	3.47E-02	3
ASCL1	transcription regulator	ND	3.47E-02	3
KDM4A	transcription regulator	ND	3.47E-02	3
CIITA	transcription regulator	ND	3.47E-02	3
RFXAP	transcription regulator	ND	3.47E-02	3
CD74	transmembrane receptor	ND	3.47E-02	3
SFTPA1	transporter	ND	3.47E-02	3
FOXO1	transcription regulator	1.385	3.56E-02	32
KRT14	other	ND	3.60E-02	17
CKAP2L	other	4.491	3.64E-02	24
OSM	cytokine	2.169	3.74E-02	10
BPIFB1	other	0	3.74E-02	10
EIF4G1	translation regulator	0.632	3.74E-02	10
IL36B	cytokine	-1.78	3.81E-02	6
PARP1	enzyme	-0.283	3.81E-02	6
PGF	growth factor	2.412	3.81E-02	6
mir-204	microRNA	-1.767	3.81E-02	6
IFNAR2	transmembrane receptor	-2.449	3.81E-02	6

SMAD3	transcription regulator	-0.344	3.98E-02	25
IRF3	transcription regulator	-0.65	4.08E-02	12
Ferritin	complex	0.555	4.12E-02	5
IL36G	cytokine	-1.294	4.12E-02	5
PARK7	enzyme	0.13	4.12E-02	5
FGF18	growth factor	-0.555	4.12E-02	5
mir-96	microRNA	0.447	4.12E-02	5
MRPL14	other	-2.236	4.12E-02	5
FURIN	peptidase	1.342	4.12E-02	5
CUX1	transcription regulator	-0.447	4.12E-02	5
TRAF3IP2	enzyme	-1.964	4.18E-02	4
SDCBP	enzyme	0.211	4.18E-02	4
KDM6B	enzyme	1	4.18E-02	4
Ctbp	group	-2	4.18E-02	4
mir-203	microRNA	-1.154	4.18E-02	4
PFDN6	other	-2	4.18E-02	4
PFDN2	other	-2	4.18E-02	4
LINC01234	other	-0.927	4.18E-02	4
IRF7	transcription regulator	-1.997	4.18E-02	4
JUNB	transcription regulator	0.058	4.20E-02	16
HAND2	transcription regulator	1.887	4.20E-02	14
ERBB2	kinase	-0.223	4.26E-02	46
TP53	transcription regulator	0.154	4.41E-02	76
SP1	transcription regulator	2.522	4.57E-02	33
TLR4	transmembrane receptor	-2.093	4.62E-02	19
Collagen type II	complex	-1.508	4.79E-02	11
ADIPOQ	other	-1.577	4.79E-02	11
EWSR1-FLI1	fusion gene/product	-2.668	4.91E-02	31

\*Not determined (ND).

Supplementary Table 5. Downstream functional effects analysis results from differential gene expression analysis baseline vs post-Mepolizumab therapy in all patients\*.

Functions Annotation	P-value	Z-score	Genes
Cell movement	1.96E-06	-0.75	572
Necrosis	2.96E-06	0.60	522
Organization of cytoskeleton	5.53E-06	1.84	320
Invasion of cells	6.26E-06	0.74	383
Microtubule dynamics	9.37E-06	2.04	233
Apoptosis	1.95E-05	1.15	570
Migration of cells	2.53E-05	-0.16	508
Necrosis of epithelial tissue	3.27E-05	-0.18	109
Organization of cytoplasm	7.31E-05	1.84	368
Formation of cellular protrusions	1.69E-04	1.90	167
Angiogenesis	2.15E-04	0.46	260
Transport of monovalent inorganic cation	2.37E-04	-0.03	61
Cell survival	2.42E-04	1.73	284
Transport of metal	3.00E-04	-0.52	110
Cell viability	3.36E-04	0.96	261
Development of vasculature	4.22E-04	0.46	262
Cell death of epithelial cells	4.49E-04	-0.54	69
Transcription	5.21E-04	1.41	642
Proliferation of connective tissue cells	6.61E-04	-0.86	99
Metabolism of N-acetylglucosamine	7.87E-04	ND	8
Monocytopoiesis	8.22E-04	-0.63	33
Cell proliferation of breast cell lines	9.19E-04	0.13	67
Activation of peripheral blood neutrophils	1.10E-03	-2.93	9
Cell death of breast cell lines	1.13E-03	-0.01	40
Cell viability of motor neurons	1.17E-03	1.11	6
Growth of connective tissue	1.18E-03	0.05	122
Transcription of RNA	1.31E-03	1.37	564
Unwinding of DNA	1.36E-03	ND	14
Transport of Na <sup>+</sup>	1.52E-03	0.25	26
Vasculogenesis	1.61E-03	1.23	207
Proliferation of epidermal cells	1.65E-03	-0.62	33
Transport of inorganic cation	1.84E-03	0.51	96
Proliferation of epithelial cells	1.90E-03	-0.74	77
Apoptosis of epithelial cells	1.97E-03	-0.28	44
Transport of metal ion	2.16E-03	0.54	89
Conformational modification of DNA	2.16E-03	ND	16
Formation of neutrophil extracellular trap	2.17E-03	0.56	7
Transport of Cu <sup>2+</sup>	2.17E-03	ND	7
Cell movement of lung cell lines	2.24E-03	2.00	20
Transport of cation	2.31E-03	0.51	105
Serine phosphorylation	2.31E-03	ND	41
Growth of skin	2.33E-03	0.40	39
Myelopoiesis of leukocytes	2.62E-03	-0.80	42
Serine phosphorylation of protein	2.81E-03	ND	8
Survival of bacteria	3.04E-03	2.07	12
Respiratory burst	3.05E-03	-0.83	21
Proliferation of lung cell lines	3.05E-03	1.50	21
Morphology of head	3.09E-03	ND	101
Reorganization of cytoskeleton	3.11E-03	1.23	33
Migration of lung cell lines	3.29E-03	1.95	17
Expression of RNA	3.54E-03	1.04	675
Glucuronidation of lipid	3.60E-03	0.85	5
Growth of epithelial tissue	3.68E-03	-0.14	159
Autophosphorylation of protein	3.69E-03	ND	58
Transcription of DNA	3.95E-03	1.15	513

\*Not determined (ND)

Supplementary Table 6. List of unique differentially expressed genes in baseline vs post-Mepolizumab therapy in separate **responder group** and corresponding values in non-responder group analysis. 50 most significant genes based on responder analysis.

Up-regulated

Down-regulated

Responders				Non-Responders			
SYMBOL	logFC	P.Value	adj.P.Val	SYMBOL	logFC	P.Value	adj.P.Val
RP11-778D9.12	1.27	1.59E-07	1.31E-04	RP11-778D9.12	0.69	1.00E-02	7.10E-02
WDR36	0.44	4.61E-07	2.11E-04	WDR36	0.27	8.16E-03	6.33E-02
AL354718.1	1.59	5.29E-07	2.32E-04	AL354718.1	0.37	2.78E-01	5.17E-01
CLUL1	1.47	7.69E-07	2.82E-04	CLUL1	0.70	3.17E-02	1.42E-01
CTD-2554C21.2	1.93	9.10E-07	2.87E-04	CTD-2554C21.2	0.31	4.41E-01	6.70E-01
MTND2P28	-2.32	1.06E-06	3.06E-04	MTND2P28	-1.48	1.09E-02	7.49E-02
RP11-497H16.6	-2.72	1.38E-06	3.65E-04	RP11-497H16.6	-1.87	5.98E-03	5.21E-02
ACACA	0.37	1.59E-06	3.75E-04	ACACA	0.09	3.28E-01	5.69E-01
LDOC1L	0.43	1.95E-06	4.27E-04	LDOC1L	0.26	1.30E-02	8.34E-02
PRKDC	0.45	2.40E-06	4.64E-04	PRKDC	0.25	2.74E-02	1.31E-01
AC004870.5	1.75	3.08E-06	5.26E-04	AC004870.5	0.68	9.35E-02	2.73E-01
MIB1	0.32	3.36E-06	5.52E-04	MIB1	0.18	3.18E-02	1.42E-01
C11orf96	-2.57	3.53E-06	5.61E-04	C11orf96	-1.26	5.56E-02	1.99E-01
MT-RNR2	-2.31	3.76E-06	5.93E-04	MT-RNR2	-1.57	1.06E-02	7.36E-02
GPR89B	1.34	4.02E-06	6.20E-04	GPR89B	0.45	1.50E-01	3.61E-01
RSPRY1	0.28	4.29E-06	6.31E-04	RSPRY1	0.13	6.50E-02	2.18E-01
NDE1	0.43	4.41E-06	6.39E-04	NDE1	0.29	7.63E-03	6.08E-02
SLC46A1	0.66	5.07E-06	6.89E-04	SLC46A1	0.35	3.41E-02	1.48E-01
COL4A3BP	0.36	5.61E-06	6.99E-04	COL4A3BP	0.25	8.95E-03	6.69E-02
RP11-51J9.5	-0.91	5.81E-06	7.07E-04	RP11-51J9.5	-0.50	4.40E-02	1.73E-01
MARVELD2	0.42	5.95E-06	7.12E-04	MARVELD2	0.17	1.25E-01	3.24E-01
CAND1	0.26	6.31E-06	7.40E-04	CAND1	0.16	2.12E-02	1.12E-01
AAK1	-0.76	6.27E-06	7.40E-04	AAK1	-0.54	9.22E-03	6.81E-02
FAM208B	0.34	6.60E-06	7.61E-04	FAM208B	0.16	7.10E-02	2.31E-01
RP13-467H17.1	1.46	6.91E-06	7.80E-04	RP13-467H17.1	0.64	7.72E-02	2.43E-01
GART	0.26	7.33E-06	8.04E-04	GART	0.11	1.18E-01	3.14E-01
CD7	-1.59	7.35E-06	8.04E-04	CD7	-1.13	9.64E-03	6.96E-02
KIF3C	1.04	7.51E-06	8.14E-04	KIF3C	0.63	1.74E-02	9.93E-02
CAPRIN1	0.35	8.05E-06	8.26E-04	CAPRIN1	0.26	6.46E-03	5.46E-02
LUZP1	0.32	8.04E-06	8.26E-04	LUZP1	0.18	3.26E-02	1.45E-01
MT-ND1	-2.15	8.03E-06	8.26E-04	MT-ND1	-1.33	2.45E-02	1.23E-01
RP11-391M20.1	-0.79	8.10E-06	8.27E-04	RP11-391M20.1	-0.19	3.69E-01	6.09E-01
PRRC2B	0.42	8.48E-06	8.34E-04	PRRC2B	0.28	1.54E-02	9.27E-02
PTK2B	0.34	8.67E-06	8.37E-04	PTK2B	0.22	1.88E-02	1.04E-01
VAMP2	-0.40	9.17E-06	8.48E-04	VAMP2	-0.25	2.15E-02	1.13E-01
TOB2	0.45	1.00E-05	8.94E-04	TOB2	0.24	5.01E-02	1.87E-01
POLR1B	0.36	1.03E-05	9.00E-04	POLR1B	0.21	2.71E-02	1.30E-01
MT-CYB	-2.17	1.03E-05	9.00E-04	MT-CYB	-1.32	2.85E-02	1.34E-01
MT-CO2	-2.19	1.04E-05	9.03E-04	MT-CO2	-1.36	2.58E-02	1.26E-01
MT-ND2	-2.13	1.05E-05	9.04E-04	MT-ND2	-1.46	1.41E-02	8.79E-02
EEA1	0.39	1.11E-05	9.45E-04	EEA1	0.22	3.40E-02	1.48E-01
ADNP	0.27	1.22E-05	9.85E-04	ADNP	0.17	2.17E-02	1.14E-01
MT-ND4	-2.14	1.30E-05	1.01E-03	MT-ND4	-1.34	2.66E-02	1.29E-01
ERF	0.47	1.34E-05	1.02E-03	ERF	0.30	1.90E-02	1.05E-01
PIK3C2A	0.28	1.37E-05	1.04E-03	PIK3C2A	0.16	3.54E-02	1.52E-01
MT-ATP6	-2.13	1.47E-05	1.07E-03	MT-ATP6	-1.30	3.12E-02	1.41E-01
KDELC1	1.28	1.48E-05	1.08E-03	KDELC1	0.40	2.33E-01	4.68E-01
GRHL2	0.38	1.52E-05	1.09E-03	GRHL2	0.25	1.71E-02	9.84E-02
MT-CO3	-2.15	1.51E-05	1.09E-03	MT-CO3	-1.31	3.19E-02	1.43E-01
MMP3	2.06	1.57E-05	1.10E-03	MMP3	1.33	1.52E-02	9.20E-02

Supplementary Table 7. List of unique differentially expressed genes baseline vs post-Mepolizumab therapy in separate **non-responder group** and corresponding values in responder group analysis. 50 most significant genes based on non-responder analysis.

Up-regulated

Down-regulated

Non-Responders			
SYMBOL	logFC	P.Value	adj.P.Val
PAPPA	3.87	2.01E-07	2.09E-04
CAMK1	1.37	3.36E-07	2.77E-04
BANK1	-0.74	3.39E-06	6.88E-04
SOGA2	1.45	3.45E-06	6.88E-04
CDC20B	1.70	4.34E-06	7.89E-04
SETD3	-0.34	4.43E-06	7.92E-04
GLUL	-0.68	4.59E-06	7.98E-04
RP11-494M8.4	2.70	5.09E-06	8.24E-04
PCOLCE2	3.78	6.47E-06	9.37E-04
FAM154A	2.24	7.17E-06	9.74E-04
LIMS2	2.53	9.38E-06	1.13E-03
NUAK1	0.72	9.37E-06	1.13E-03
AC074011.2	3.06	9.60E-06	1.14E-03
PRKAA2	-0.74	1.11E-05	1.26E-03
MOCS2	-0.37	1.12E-05	1.26E-03
AC087499.7	3.31	1.23E-05	1.32E-03
RP11-747H12.6	-3.85	1.34E-05	1.38E-03
COX14	-0.65	1.46E-05	1.44E-03
MPZL1	-0.51	1.55E-05	1.50E-03
RP11-553P9.1	2.04	1.77E-05	1.62E-03
HRSP12	-0.49	1.93E-05	1.72E-03
RP11-235G24.3	3.04	2.35E-05	1.97E-03
RP11-1149O23.3	-0.86	2.40E-05	1.97E-03
RP11-305L7.7	1.74	2.46E-05	2.00E-03
DRAM1	-0.81	2.54E-05	2.02E-03
UGT2B17	-3.85	2.68E-05	2.09E-03
ARHGEF26	0.96	2.78E-05	2.15E-03
ZNF648	-1.73	3.12E-05	2.32E-03
LEPREL1	1.25	3.34E-05	2.39E-03
RP11-44N21.1	1.56	3.83E-05	2.57E-03
ZNHIT6	-0.71	3.85E-05	2.58E-03
ZNF833P	2.05	3.86E-05	2.58E-03
RP11-707O23.5	-6.20	4.36E-05	2.83E-03
CLIC4	-0.69	4.47E-05	2.90E-03
CXCL10	-4.80	4.67E-05	2.97E-03
USF1	-0.47	4.82E-05	3.05E-03
ZNF846	0.78	5.03E-05	3.13E-03
RHOQ	-0.34	5.15E-05	3.18E-03
RP11-177C12.1	1.94	5.24E-05	3.21E-03
LST1	-2.15	5.36E-05	3.25E-03
RP11-488I20.8	3.33	5.51E-05	3.32E-03
TMEM194A	0.57	5.57E-05	3.34E-03
RP11-110G21.2	-1.71	5.68E-05	3.37E-03
ZDHHC12	-0.43	5.86E-05	3.43E-03
AP000704.5	1.57	5.96E-05	3.43E-03
SPATA22	3.49	6.11E-05	3.49E-03
KCNJ15	-0.69	6.80E-05	3.75E-03
P4HA3	2.69	6.99E-05	3.81E-03
ETV7	-1.10	7.33E-05	3.93E-03
FBXL20	0.74	7.60E-05	4.00E-03

Responders			
SYMBOL	logFC	P.Value	adj.P.Val
PAPPA	0.65	1.26E-01	2.88E-01
CAMK1	0.42	2.24E-02	9.84E-02
BANK1	-0.26	2.44E-02	1.04E-01
SOGA2	0.47	3.02E-02	1.18E-01
CDC20B	0.66	1.05E-02	6.08E-02
SETD3	-0.08	1.20E-01	2.80E-01
GLUL	-0.25	1.74E-02	8.34E-02
RP11-494M8.4	0.65	1.00E-01	2.51E-01
PCOLCE2	1.15	3.20E-02	1.22E-01
FAM154A	0.57	8.51E-02	2.27E-01
LIMS2	0.67	7.66E-02	2.13E-01
NUAK1	0.24	3.92E-02	1.38E-01
AC074011.2	0.75	9.88E-02	2.49E-01
PRKAA2	-0.25	4.05E-02	1.41E-01
MOCS2	-0.17	8.31E-03	5.24E-02
AC087499.7	1.15	2.87E-02	1.14E-01
RP11-747H12.6	-1.07	8.39E-02	2.25E-01
COX14	-0.29	9.33E-03	5.64E-02
MPZL1	-0.18	4.37E-02	1.48E-01
RP11-553P9.1	0.55	1.04E-01	2.57E-01
HRSP12	-0.14	8.80E-02	2.32E-01
RP11-235G24.3	0.06	9.03E-01	9.46E-01
RP11-1149O23.3	-0.33	2.93E-02	1.16E-01
RP11-305L7.7	0.67	2.19E-02	9.72E-02
DRAM1	-0.30	3.70E-02	1.33E-01
UGT2B17	-1.32	4.02E-02	1.40E-01
ARHGEF26	0.42	1.11E-02	6.34E-02
ZNF648	-0.32	2.91E-01	4.84E-01
LEPREL1	0.36	9.51E-02	2.43E-01
RP11-44N21.1	0.64	1.97E-02	9.07E-02
ZNHIT6	-0.32	1.30E-02	6.93E-02
ZNF833P	0.92	1.04E-02	6.06E-02
RP11-707O23.5	-2.34	1.57E-02	7.84E-02
CLIC4	-0.12	3.22E-01	5.15E-01
CXCL10	-1.97	1.36E-02	7.14E-02
USF1	-0.23	8.01E-03	5.13E-02
ZNF846	0.33	2.10E-02	9.45E-02
RHOQ	-0.09	1.44E-01	3.13E-01
RP11-177C12.1	0.64	5.35E-02	1.68E-01
LST1	-0.74	5.54E-02	1.71E-01
RP11-488I20.8	1.04	7.40E-02	2.08E-01
TMEM194A	0.28	7.79E-03	5.05E-02
RP11-110G21.2	-0.71	2.17E-02	9.64E-02
ZDHHC12	-0.20	1.22E-02	6.67E-02
AP000704.5	0.19	4.70E-01	6.50E-01
SPATA22	1.44	1.82E-02	8.60E-02
KCNJ15	-0.23	7.16E-02	2.04E-01
P4HA3	0.83	4.99E-02	1.61E-01
ETV7	-0.51	1.37E-02	7.18E-02
FBXL20	0.08	5.56E-01	7.17E-01

Supplementary Table 8. List of disease associations from differential gene expression analysis in separate responder or non-responder groups. Due to a large number of disease associations only auto-immune, infectious, inflammatory, or respiratory diseases have been shown.

Common						
Diseases Annotation	Group	P-value	Genes	Group	P-value	Genes
Non-malignant disorder	R	9.48E-13	501	NR	6.50E-11	373
Benign lesion	R	1.36E-07	259	NR	2.21E-06	192
Viral Infection	R	8.41E-07	282	NR	3.61E-09	227
Infection by RNA virus	R	8.21E-06	166	NR	1.52E-06	131
COVID-19	R	9.42E-06	129	NR	9.18E-07	104
Fibrosis	R	1.39E-04	121	NR	2.87E-03	86
Immune mediated inflammatory disease	R	1.41E-04	334	NR	1.48E-05	258
Systemic autoimmune syndrome	R	4.27E-04	334	NR	1.64E-05	261
Inflammation of organ	R	4.38E-04	213	NR	2.09E-04	163
Eosinophilia	R	6.55E-04	37	NR	1.93E-03	28

Non-Responders only			
Diseases Annotation	Group	P-value	Genes
Psoriasis	NR	2.84E-06	123
Skin lesion	NR	3.07E-06	1407
Diabetes mellitus	NR	5.90E-06	172
Inflammation of muscle	NR	6.14E-06	34
Severe COVID-19	NR	1.19E-05	40
Lupus erythematosus	NR	1.36E-05	100
Dermatomyositis	NR	1.44E-05	29
Asthma	NR	1.52E-05	52
Systemic lupus erythematosus	NR	2.68E-05	96
Tuberculosis	NR	4.14E-05	42
Acute respiratory disorder	NR	4.70E-05	68
Chronic pulmonary disease	NR	5.50E-05	42
Severe inflammatory disorder	NR	5.87E-05	63
Inflammatory Bowel Disease	NR	1.45E-04	84
Rheumatoid arthritis	NR	1.76E-04	149
Sepsis	NR	2.32E-04	35
Glomerulonephritis	NR	2.75E-04	33
Chronic inflammatory disorder	NR	2.98E-04	217
Viral respiratory infection	NR	3.08E-04	45
Severe pulmonary disease	NR	3.13E-04	47
Chronic obstructive pulmonary disease	NR	3.31E-04	37
Crohn disease	NR	3.37E-04	62
Non-traumatic arthropathy	NR	4.11E-04	175
Severe acute respiratory syndrome	NR	4.70E-04	42
Respiratory distress	NR	7.40E-04	53
Infection of respiratory tract	NR	7.62E-04	51
Rheumatic Disease	NR	7.68E-04	194
Acne	NR	7.90E-04	23
Inflammation of joint	NR	9.36E-04	183
Lower respiratory tract disorder	NR	9.83E-04	60
Insulin-dependent diabetes mellitus	NR	1.04E-03	49
Inflammation of airway	NR	1.08E-03	56
Inflammation of respiratory system component	NR	1.37E-03	65
Lichen planus	NR	1.50E-03	23
Abnormality of skin morphology	NR	1.67E-03	72
Early stage COVID-19	NR	2.19E-03	3
Immunoglobulin deficiency	NR	2.40E-03	13
Replication of virus	NR	2.57E-03	30
Quantity of virus	NR	2.94E-03	5
Polymyositis	NR	3.40E-03	10
Chronic respiratory disorder	NR	3.42E-03	43
Chronic large plaque psoriasis	NR	3.62E-03	6



Chronic small plaque psoriasis	NR	3.62E-03	6
Dermatitis	NR	3.77E-03	79

Responders only			
Diseases Annotation	Group	P-value	Genes
Infection by coronavirus	R	1.08E-05	130
Abdominal lesion	R	5.03E-05	2565

Supplementary Table 9. Upstream regulator analysis results from differential gene expression analysis in separate responder (R) or non-responder (NR) groups\*.

Upstream Regulator	Molecule Type	Z-score	P-value	Genes	Group
TLR3	transmembrane receptor	-1.30	1.75E-06	23	NR
IL1B	cytokine	-2.04	1.83E-06	41	NR
STAT1	transcription regulator	-4.12	1.62E-05	26	NR
Interferon alpha	group	-2.12	4.26E-05	39	NR
TREX1	enzyme	4.20	9.12E-05	25	NR
IL1RN	cytokine	3.90	2.66E-04	19	NR
MAP2K3	kinase	-2.00	2.81E-04	4	NR
MAP2K6	kinase	-2.00	2.81E-04	4	NR
USP8	peptidase	3.32	4.34E-04	11	NR
RNASEH2B	other	4.26	4.71E-04	22	NR
TSLP	cytokine	1.12	6.67E-04	10	NR
IRF7	transcription regulator	-2.00	1.26E-03	4	NR
MYC	transcription regulator	1.53	1.81E-03	20	NR
CXCL8	cytokine	0.88	1.85E-03	13	NR
TEAD1	transcription regulator	1.96	1.89E-03	14	NR
TCR	complex	-1.48	2.16E-03	40	NR
IKK (complex)	complex	ND	2.17E-03	3	NR
KDM4A	transcription regulator	ND	2.17E-03	3	NR
NFIX	transcription regulator	ND	2.17E-03	3	NR
RELB	transcription regulator	ND	2.17E-03	3	NR
SFTPA1	transporter	ND	2.17E-03	3	NR
PRL	cytokine	-2.51	2.29E-03	19	NR
PTGS2	enzyme	-1.81	2.38E-03	7	NR
STAG2	other	3.46	2.89E-03	12	NR
TEAD2	transcription regulator	2.31	2.89E-03	12	NR
IL4	cytokine	2.23	3.13E-03	21	NR
CHI3L1	enzyme	ND	3.33E-03	8	NR
CCL2	cytokine	0.62	3.56E-03	11	NR
CAMP	other	-0.50	4.36E-03	10	NR
CHD7	enzyme	ND	5.20E-03	5	NR
SNCA	enzyme	ND	5.79E-03	19	NR
FCGR2B	transmembrane receptor	1.98	7.10E-03	4	NR
Ferritin	complex	0.00	7.10E-03	4	NR
SATB2	transcription regulator	-0.51	7.14E-03	10	NR
TLR7/8	group	-1.49	7.14E-03	10	NR
RTKN	other	ND	7.84E-03	3	NR
S1PR1	G-protein coupled receptor	ND	7.84E-03	3	NR
S1PR3	G-protein coupled receptor	ND	7.84E-03	3	NR
CREBBP	transcription regulator	ND	8.52E-03	5	NR
IKBKE	kinase	-0.45	8.52E-03	5	NR
NPM1	transcription regulator	0.78	1.02E-02	26	NR
RAG2	enzyme	0.54	1.05E-02	14	NR
RNY3	other	-2.83	1.10E-02	8	NR
IL33	cytokine	1.27	1.11E-02	10	NR
SMARCC1	transcription regulator	ND	1.27E-02	4	NR
VDR	transcription regulator	0.28	1.27E-02	4	NR
STAT3	transcription regulator	-0.90	1.30E-02	20	NR
SETBP1	transcription regulator	0.00	1.56E-02	16	NR
LIN28B	other	0.00	1.63E-02	6	NR
GAPLINC	other	ND	1.68E-02	2	NR
GK	kinase	ND	1.68E-02	2	NR
HISTONE	group	ND	1.68E-02	2	NR
IFI16	transcription regulator	ND	1.68E-02	2	NR
IRX1	transcription regulator	ND	1.68E-02	2	NR
MAP2K4	kinase	ND	1.68E-02	2	NR
MUS81	enzyme	ND	1.68E-02	2	NR
PML	transcription regulator	ND	1.68E-02	2	NR

RPL11	other	ND	1.68E-02	2	NR
S1PR2	G-protein coupled receptor	ND	1.68E-02	2	NR
SRSF2	transcription regulator	ND	1.68E-02	2	NR
ZBTB7A	transcription regulator	ND	1.68E-02	2	NR
LILRB4	other	ND	1.77E-02	3	NR
PDE4B	enzyme	ND	1.77E-02	3	NR
TLR9	transmembrane receptor	-3.29	1.86E-02	11	NR
CHRNA3	transmembrane receptor	-0.09	2.06E-02	4	NR
IFNAR2	transmembrane receptor	-2.00	2.06E-02	4	NR
KPNB1	other	2.00	2.06E-02	4	NR
PROX1	transcription regulator	0.85	2.06E-02	4	NR
CD276	other	2.45	2.18E-02	6	NR
KRT14	other	ND	2.57E-02	9	NR
MAP2K1/2	group	-1.45	2.65E-02	5	NR
MMP14	peptidase	-1.39	2.65E-02	5	NR
IFNA2	cytokine	-2.04	2.73E-02	8	NR
CEBPB	transcription regulator	-0.51	2.82E-02	10	NR
NRXN1	transporter	ND	2.85E-02	6	NR
PTPN3	phosphatase	1.09	2.85E-02	6	NR
S100A8	other	-2.00	3.09E-02	4	NR
IGF2R	transmembrane receptor	ND	3.20E-02	3	NR
KLF1	transcription regulator	ND	3.20E-02	3	NR
RASSF8	other	ND	3.20E-02	3	NR
ZNF100	transcription regulator	ND	3.20E-02	3	NR
ZNF254	transcription regulator	ND	3.20E-02	3	NR
ZNF429	transcription regulator	ND	3.20E-02	3	NR
ZNF43	transcription regulator	ND	3.20E-02	3	NR
ZNF431	transcription regulator	ND	3.20E-02	3	NR
ZNF528	other	ND	3.20E-02	3	NR
ZNF665	other	ND	3.20E-02	3	NR
ZNF708	other	ND	3.20E-02	3	NR
ZNF85	transcription regulator	ND	3.20E-02	3	NR
ZNF91	transcription regulator	ND	3.20E-02	3	NR
CD36	transmembrane receptor	-0.85	3.64E-02	9	NR
TLR7	transmembrane receptor	-2.33	3.64E-02	9	NR
FOXC1	transcription regulator	-3.30	3.86E-02	18	NR
MRTFA	transcription regulator	0.45	3.98E-02	8	NR
GLIS1	transcription regulator	-0.38	4.29E-02	7	NR
CD14	transmembrane receptor	-1.95	4.37E-02	4	NR
DDIT3	transcription regulator	-1.10	4.37E-02	4	NR
PRKCE	kinase	1.98	4.37E-02	4	NR
CD44	other	0.56	4.54E-02	6	NR
EZH2	transcription regulator	1.97	4.58E-02	11	NR
CD28	transmembrane receptor	-1.13	4.59E-02	14	NR
CCN6	growth factor	ND	4.60E-02	2	NR
CFLAR	other	ND	4.60E-02	2	NR
CIITA	transcription regulator	ND	4.60E-02	2	NR
Cpla2	group	ND	4.60E-02	2	NR
CTBP1	enzyme	ND	4.60E-02	2	NR
GALNT6	enzyme	ND	4.60E-02	2	NR
LRP1	transmembrane receptor	ND	4.60E-02	2	NR
MAP2K7	kinase	ND	4.60E-02	2	NR
MMP12	peptidase	ND	4.60E-02	2	NR
NLRP3	other	ND	4.60E-02	2	NR
NOX5	ion channel	ND	4.60E-02	2	NR
NRP2	kinase	ND	4.60E-02	2	NR
SUZ12	enzyme	ND	4.60E-02	2	NR
TGM2	enzyme	ND	4.60E-02	2	NR
Tnf receptor	group	ND	4.60E-02	2	NR
TNFAIP6	other	ND	4.60E-02	2	NR
XIAP	enzyme	ND	4.60E-02	2	NR

RNASE2	enzyme	-1.59	4.64E-02	5	NR
LONP1	peptidase	-2.34	6.55E-07	13	R
MT-TE	other	ND	5.84E-06	7	R
CXCL12	cytokine	-1.25	6.20E-04	19	R
mir-2392	microRNA	2.44	6.57E-04	6	R
MALSU1	other	-2.24	9.34E-04	5	R
POLRMT	enzyme	-2.24	9.34E-04	5	R
NFKBIZ	transcription regulator	-1.91	9.80E-04	7	R
PKM	kinase	0.44	1.99E-03	7	R
MRPL14	other	-2.24	2.79E-03	5	R
MAP3K7	kinase	-1.70	3.55E-03	6	R
PTEN	phosphatase	0.24	5.44E-03	8	R
ANLN	other	-1.00	5.86E-03	16	R
AURK	group	-1.00	5.86E-03	16	R
PARP1	enzyme	ND	6.33E-03	5	R
ZEB1	transcription regulator	0.29	9.81E-03	9	R
HSF1	transcription regulator	2.45	1.00E-02	25	R
FGF7	growth factor	ND	1.13E-02	4	R
ITGAV	transmembrane receptor	-1.96	1.13E-02	4	R
mir-23	microRNA	-1.09	1.13E-02	4	R
GDF2	growth factor	-0.07	1.22E-02	5	R
CCL5	cytokine	-0.83	1.50E-02	13	R
MRTFA	transcription regulator	1.24	1.50E-02	11	R
FOSL1	transcription regulator	1.97	1.71E-02	8	R
ITGA6	transmembrane receptor	ND	1.98E-02	3	R
OTUD7B	peptidase	ND	1.98E-02	3	R
Raf	group	ND	1.98E-02	3	R
SCAP	other	ND	1.98E-02	3	R
TLR5	transmembrane receptor	ND	1.98E-02	3	R
TNFSF13B	cytokine	ND	1.98E-02	3	R
BCL3	transcription regulator	-1.17	2.08E-02	5	R
FURIN	peptidase	0.00	2.26E-02	4	R
ITGB3	transmembrane receptor	-1.00	2.26E-02	4	R
TP63	transcription regulator	-0.19	2.93E-02	51	R
AKT2	kinase	ND	3.20E-02	2	R
CTBP2	transcription regulator	ND	3.20E-02	2	R
GAS6	growth factor	ND	3.20E-02	2	R
GATAD2B	transcription regulator	ND	3.20E-02	2	R
IL1R2	transmembrane receptor	ND	3.20E-02	2	R
IQGAP1	other	ND	3.20E-02	2	R
LILRB1	transmembrane receptor	ND	3.20E-02	2	R
MAPKAPK2	kinase	ND	3.20E-02	2	R
mir-26	microRNA	ND	3.20E-02	2	R
NCOR1	transcription regulator	ND	3.20E-02	2	R
NEDD4	enzyme	ND	3.20E-02	2	R
NFE2L1	transcription regulator	ND	3.20E-02	2	R
PTGER4	G-protein coupled receptor	ND	3.20E-02	2	R
RFX5	transcription regulator	ND	3.20E-02	2	R
SCGB1A1	cytokine	ND	3.20E-02	2	R
TP53	transcription regulator	0.50	3.54E-02	44	R
LGALS3	other	1.07	3.89E-02	4	R
NAMPT	cytokine	-0.83	3.89E-02	4	R
NR3C2	ligand-dependent nuclear receptor	ND	3.89E-02	4	R
SMAD1	transcription regulator	-1.98	3.89E-02	4	R
DUX4	transcription regulator	-0.43	3.98E-02	9	R
ARID1A	transcription regulator	0.82	3.99E-02	32	R
HAND1	transcription regulator	ND	4.30E-02	3	R
IL22RA1	transmembrane receptor	ND	4.30E-02	3	R
KIF26A	other	ND	4.30E-02	3	R
mir-148	microRNA	ND	4.30E-02	3	R
PIK3R1	kinase	ND	4.30E-02	3	R

STK4	kinase	ND	4.30E-02	3	R
TFAP2A	transcription regulator	ND	4.30E-02	3	R
TLR6	transmembrane receptor	ND	4.30E-02	3	R
VIM	other	ND	4.30E-02	3	R
TGFBR2	kinase	0.00	4.66E-02	19	R
FBN1	other	-1.25	4.78E-02	5	R
AGO2	translation regulator	2.44	5.13E-02	6	R

\*Not determined (ND)

Supplementary Table 10. Downstream functional effects analysis results from differential gene expression analysis in separate responder (R) or non-responder (NR) groups\*.

Functional Annotation	P-value	Z-score	Genes	Group
Binding of blood cells	1.44E-05	-0.55	54	NR
Movement of CD4+ T-lymphocytes	2.43E-05	0.00	8	NR
Adhesion of blood cells	3.24E-05	-0.70	48	NR
Transport of monosaccharide	3.98E-05	-0.08	20	NR
Chemotaxis	8.54E-05	-0.68	67	NR
Cell viability of granulocytes	9.40E-05	0.85	9	NR
Transport of carbohydrate	9.54E-05	-0.54	25	NR
Transport of hexose	1.25E-04	-0.36	18	NR
Apoptosis of B lymphoblastoid cell lines	1.26E-04	-2.01	7	NR
Cell spreading	1.32E-04	0.35	27	NR
Cell death of immune cells	1.86E-04	0.50	53	NR
Migration of CD4+ T-lymphocytes	1.97E-04	-1.34	5	NR
Cell movement of endothelial cell lines	1.98E-04	-0.77	26	NR
Adhesion of immune cells	2.26E-04	-0.30	41	NR
Phosphorylation of protein	2.27E-04	-1.40	98	NR
Serine phosphorylation	2.32E-04	0.56	35	NR
Binding of leukocytes	2.71E-04	-0.88	44	NR
Cell death of blood cells	2.78E-04	0.48	55	NR
Activation of cells	2.89E-04	-0.57	76	NR
Cell viability	3.23E-04	-1.09	118	NR
Cell survival	3.41E-04	-0.35	127	NR
Apoptosis of lymphatic system cells	3.48E-04	0.55	28	NR
Transport of D-glucose	3.60E-04	-0.36	15	NR
Inflammatory response	3.67E-04	-0.35	73	NR
Survival of neural cells	3.92E-04	1.22	16	NR
Cell viability of myeloid cells	4.08E-04	1.64	12	NR
Cell movement of epithelial cells	4.17E-04	-0.28	21	NR
Cell viability of leukocytes	4.25E-04	0.53	20	NR
Cellular homeostasis	4.60E-04	-2.05	145	NR
Cytotoxicity of cytotoxic T cells	5.18E-04	-2.61	7	NR
Morphology of tumor cell lines	5.29E-04	ND	19	NR
Protein kinase cascade	5.56E-04	-0.73	63	NR
Phosphorylation of L-amino acid	5.91E-04	0.97	29	NR
Apoptosis of lymphocytes	5.98E-04	0.13	27	NR
Transport of monovalent inorganic cation	5.98E-04	0.60	27	NR
Shape change of vascular endothelial cells	6.09E-04	-0.31	15	NR
Cell movement of endothelial cells	6.25E-04	0.08	65	NR
Migration of skin cell lines	6.32E-04	-0.39	11	NR
Binding of myeloid cells	7.52E-04	-0.29	26	NR
Cell death of lymphocytes	7.54E-04	0.34	31	NR
Interaction of carbohydrate	8.78E-04	-1.74	13	NR
Proliferation of neuronal cells	9.64E-04	1.96	19	NR
Proliferation of lymphoblastoid cell lines	1.01E-03	0.45	16	NR
Cell spreading of endothelial cells	1.05E-03	-0.43	9	NR
Phosphorylation of peptide	1.08E-03	0.98	35	NR
Apoptosis of tumor cell lines	1.14E-03	-1.39	81	NR
Sprouting of vascular endothelial cells	1.21E-03	0.55	11	NR
Apoptosis of leukocytes	1.24E-03	-0.05	38	NR
Catabolism of L-tryptophan	1.27E-03	ND	4	NR
Clustering of cells	1.27E-03	ND	4	NR
Formation of hemidesmosomes	1.27E-03	0.00	4	NR
Migration of endothelial cell lines	1.33E-03	-0.63	20	NR
Import of D-glucose	1.38E-03	-0.63	10	NR
Metabolism of peptide	1.47E-03	1.15	44	NR
Cell death of T lymphocytes	1.50E-03	0.50	23	NR
Transport of inorganic cation	1.51E-03	1.28	42	NR
Apoptosis of T lymphocytes	1.58E-03	0.10	20	NR

Transport of metal ion	1.70E-03	1.71	39	NR
Interaction of protein	1.75E-03	1.07	21	NR
Binding of granulocytes	1.76E-03	-0.09	18	NR
Binding of carbohydrate	1.80E-03	-1.31	12	NR
Serine phosphorylation of peptide	1.83E-03	0.80	31	NR
Cell-cell contact	1.86E-03	0.48	51	NR
Response of phagocytes	1.90E-03	-0.86	16	NR
Cell movement of dermal cells	1.94E-03	-0.73	15	NR
Growth of neurites	1.94E-03	2.06	15	NR
Migration of epithelial cells	1.94E-03	0.13	15	NR
Outgrowth of neurites	1.94E-03	1.87	14	NR
Stimulation of cells	2.11E-03	-0.72	18	NR
Proliferation of neural cells	2.15E-03	2.06	24	NR
Internalization of carbohydrate	2.16E-03	-0.11	11	NR
Density of microvessel	2.19E-03	ND	3	NR
Migration of cerebral cortex cells	2.19E-03	ND	3	NR
Migration of helper T lymphocytes	2.19E-03	ND	3	NR
Mutagenesis of cells	2.19E-03	ND	3	NR
Parturition	2.19E-03	ND	3	NR
Apoptosis of blood cells	2.30E-03	-0.23	39	NR
Branching of cells	2.31E-03	1.20	16	NR
I-kappaB kinase/NF-kappaB cascade	2.34E-03	-1.64	26	NR
Migration of thyroid tumor cell lines	2.36E-03	0.82	8	NR
Cell movement of skin cell lines	2.40E-03	-1.29	13	NR
Cell movement of keratinocytes	2.41E-03	-1.12	14	NR
Formation of gland	2.42E-03	ND	7	NR
Transmigration of cells	2.59E-03	-0.86	20	NR
Cell viability of squamous cell carcinoma cell lines	2.82E-03	1.29	11	NR
Synthesis of DNA	2.86E-03	1.13	37	NR
Modification of peptide	2.88E-03	0.98	36	NR
Activation of CD4+ T-lymphocytes	2.94E-03	ND	5	NR
Killing of lymphocytes	2.94E-03	0.45	5	NR
Morphogenesis of embryonic tissue	2.94E-03	ND	5	NR
Binding of polysaccharide	2.99E-03	-1.07	9	NR
Transport of metal	3.00E-03	0.96	45	NR
Outgrowth of cells	3.36E-03	1.78	16	NR
Development of fibroblasts	3.38E-03	1.52	8	NR
Transmembrane receptor protein tyrosine kinase signaling pathway	3.38E-03	ND	8	NR
Apoptosis of lymphoblastoid cell lines	3.40E-03	-2.40	10	NR
Migration of neural cells	3.40E-03	-0.89	10	NR
Apoptosis of schwannoma cell lines	3.42E-03	-1.12	4	NR
Interphase of skin cancer cell lines	3.42E-03	ND	4	NR
Migration of central nervous system cells	3.42E-03	ND	4	NR
Immune response of phagocytes	3.53E-03	-0.63	15	NR
Response of myeloid cells	3.53E-03	-0.56	15	NR
Hematopoiesis of mononuclear leukocytes	3.55E-03	-1.60	35	NR
Intercellular communication	3.57E-03		23	NR
Colony formation of epithelial cell lines	3.62E-03	-0.39	6	NR
Formation of mammary gland	3.62E-03	ND	6	NR
Synthesis of nucleoside diphosphates	3.62E-03	ND	6	NR
Binding of blood platelets	3.64E-03	0.97	11	NR
Branching of epithelial tissue	3.74E-03	0.90	13	NR
Invasion of tumor cell lines	1.02E-07	2.16	206	R
Cell movement of tumor cell lines	1.44E-06	1.85	124	R
Migration of tumor cell lines	4.58E-06	2.13	114	R
Invasion of carcinoma cell lines	5.07E-06	1.73	82	R
Activation of peripheral blood neutrophils	7.27E-06	-2.93	9	R
Organization of cytoskeleton	8.21E-06	1.37	189	R
Transcription	2.02E-05	2.34	370	R
Invasion of breast cancer cell lines	4.99E-05	1.60	65	R
Expression of RNA	7.88E-05	1.96	390	R

Microtubule dynamics	8.20E-05	1.46	136	R
Organization of cytoplasm	1.12E-04	1.37	215	R
Interaction of epithelial cells	1.67E-04	1.39	21	R
Hydrolysis of nucleotide	2.13E-04	1.82	18	R
Cell movement of fibrosarcoma cell lines	2.79E-04	2.02	20	R
Cell death of epithelial cells	3.03E-04	-1.16	46	R
Invasion of thyroid tumor cell lines	3.59E-04	0.33	10	R
Synthesis of nucleotide	4.15E-04	-0.59	43	R
Migration of fibrosarcoma cell lines	4.18E-04	1.89	18	R
Reorganization of cytoskeleton	4.52E-04	1.24	23	R
Formation of nuclear foci	5.83E-04	-2.53	23	R
Apoptosis of epithelial cells	5.89E-04	-1.22	29	R
Detachment of cells	6.36E-04	-0.46	10	R
Formation of cellular protrusions	7.05E-04	1.53	98	R
Quantity of superoxide	9.38E-04	-2.24	5	R
Transport of heavy metal	9.48E-04	-1.13	24	R
Degradation of hydrogen peroxide	9.85E-04	ND	7	R

\*Not determined (ND)



Supplementary Table 11. List of differentially methylated CpG sites baseline vs post-Mepolizumab therapy in all patients.

CpG site	logFC	adj.P.Val	Location (Genome 37)	Annotated gene
cg09261794	0.0274	1.06E-02	Chromosome 6 - 33147897	COL11A2
cg16243351	0.0134	1.59E-02	Chromosome 11 - 35453590	PAMR1
cg17748184	0.0045	1.64E-02	Chromosome 1 - 222639024	-
cg15733917	-0.0078	1.68E-02	Chromosome 2 - 109150694	-
cg13551227	0.0120	1.69E-02	Chromosome 10 - 103604019	KCNIP2
cg07252627	0.0145	2.10E-02	Chromosome 19 - 18378899	KIAA1683
cg11298262	0.0107	2.10E-02	Chromosome 20 - 56009992	-
cg22681114	0.0271	2.10E-02	Chromosome 6 - 31123764	CCHCR1
cg06788631	0.0079	2.26E-02	Chromosome 10 - 101300607	-
cg05214404	0.0060	2.32E-02	Chromosome 4 - 37455362	C4orf19
cg09715562	0.0411	2.32E-02	Chromosome 22 - 19072685	DGCR2
cg10648252	0.0125	2.32E-02	Chromosome 7 - 101469088	CUX1
cg18471664	0.0065	2.32E-02	Chromosome 3 - 5028143	-
cg14080745	0.0045	2.44E-02	Chromosome 20 - 61556425	DIDO1
cg24669932	0.0109	2.66E-02	Chromosome 1 - 8877431	RERE
cg20411278	0.0200	3.29E-02	Chromosome 17 - 45728574	KPNB1
cg24670497	0.0113	3.29E-02	Chromosome 1 - 16068127	TMEM82
cg18301742	-0.0038	3.31E-02	Chromosome 21 - 34100210	PAXBP1-AS1
cg05683632	0.0130	3.67E-02	Chromosome 19 - 41253983	C19orf54
cg09423080	0.0018	3.67E-02	Chromosome 13 - 76111751	COMMD6
cg26066560	0.0683	3.67E-02	Chromosome 7 - 2086333	MAD1L1
cg02151918	0.0165	3.71E-02	Chromosome 11 - 70211268	PPFIA1
cg02635677	0.0368	3.71E-02	Chromosome 5 - 176823320	SLC34A1
cg03010429	0.0163	3.71E-02	Chromosome 2 - 134352494	-
cg05002732	0.0089	3.71E-02	Chromosome 11 - 19262474	E2F8
cg05095252	0.0444	3.71E-02	Chromosome 2 - 150308042	LYPD6
cg06211272	0.0033	3.71E-02	Chromosome 1 - 59012675	OMA1
cg06301443	0.0094	3.71E-02	Chromosome 22 - 19807266	GNB1L
cg08369629	0.1184	3.71E-02	Chromosome 8 - 53598501	RB1CC1
cg09099761	0.0192	3.71E-02	Chromosome 10 - 72081690	LRRC20
cg13469617	0.0243	3.71E-02	Chromosome 21 - 40119488	LINC00114
cg16226507	0.0082	3.71E-02	Chromosome 5 - 180432814	BTNL3
cg16373535	0.0176	3.71E-02	Chromosome 5 - 1923122	-
cg17422500	0.0031	3.71E-02	Chromosome 1 - 249152952	ZNF692
cg18663341	0.0121	3.71E-02	Chromosome 7 - 45148416	TBRG4
cg18900832	0.0335	3.71E-02	Chromosome 15 - 25303214	SNORD116-4
cg18918010	0.0105	3.71E-02	Chromosome 8 - 123871905	ZHX2
cg20256649	0.0173	3.71E-02	Chromosome 2 - 1941523	MYT1L
cg21136271	0.0132	3.71E-02	Chromosome 15 - 93146384	-
cg22347697	0.0319	3.71E-02	Chromosome 19 - 47827163	-
cg23406506	0.0047	3.71E-02	Chromosome 4 - 110736542	GAR1
cg27406678	0.0104	3.71E-02	Chromosome 4 - 85417612	NKX6-1
cg24714082	0.0241	3.90E-02	Chromosome 1 - 167595191	-
ch.7.3189261R	0.0080	3.90E-02	Chromosome 7 - 151489100	PRKAG2

cg18427648	0.0050	3.92E-02	Chromosome 4 - 146403869	SMAD1
cg16827359	0.0219	4.21E-02	Chromosome 22 - 49554562	-
cg05579339	0.0040	4.54E-02	Chromosome 14 - 78226979	C14orf178, SNW1
cg07906473	0.0154	4.54E-02	Chromosome 16 - 88573286	ZFPM1
cg12823530	0.0158	4.54E-02	Chromosome 14 - 24551984	NRL
cg14876117	0.0739	4.54E-02	Chromosome 14 - 51428973	-
cg20207310	0.0070	4.54E-02	Chromosome 1 - 244614789	ADSS
cg26744946	0.0226	4.54E-02	Chromosome 8 - 145065833	GRINA
cg27333547	0.0218	4.54E-02	Chromosome 16 - 88106229	BANP

Supplementary Table 12. List of correlated differentially methylated CpG sites and differentially expressed genes from the baseline vs post-Mepolizumab therapy in all patients. List show the CpG site and genes it correlates with.

CpG site	No. of genes	Genes
cg09261794	110	PCDH17, DMD, RP11-262H14.4, AR, ELOVL2, RP1-151F17.2, RPL5P2, FCF1P8, SRGAP3, BRIP1, GALNT13, ADCYAP1, ANK3, FLRT3, LGMN, ANKRD6, LINC00885, SLC16A14P1, CTD-2331H12.5, RP11-362F19.1, COL21A1, HNRNPA1P34, NANOS2, FMO3, FAM13A, CDC14A, LPGAT1, WBSCR27, EFNB3, LINC00939, RP11-296E23.2, MARK2P13, BBS2, AIFM3, CCDC26, PDGFD, RP11-44F21.5, VMAC, SMOX, EID2B, FZD6, C9orf163, PLXNA2, FAM179B, LINC00482, PCDH7, CCP110, SLC46A2, ABCC6P2, AC010890.1, C1orf168, CYBB, KIF27, ABCC5, LRMP, MORN1, SLC23A2, NEBL, NDN, CCDC81, NGGT1, RP11-19E11.1, ADIRF-AS1, CACHD1, ENPP7, NTN5, PRSS36, TMEM131, ZNF853, SLC22A4, FAM174A, ST6GAL2, ZNF404, DNAH17-AS1, ZNF516, GPX8, PLCXD3, THAP10, ADAM12, CTD-2314G24.2, MLF1, MAML1, CLIC2, ZBTB26, ZNF440, RP11-3L10.3, ACVR1B, RP11-60E8.4, HERC1, CXorf22, XKRYP6, LRWD1, PFKM, SLC20A2, CYFIP2, ABCC4, RP11-428K3.1, PGM2L1, MRV1-AS1, CELSR1, TBC1D2B, PSG5, ZBTB10, CLCA1, KMT2A, SLC7A2, AC116609.1, RP11-384F7.2, CDC7, FCGR3A
cg16243351	6	RP11-384F7.2, PCDHGB3, CTC-203F4.2, CTD-2314G24.2, TOR1AIP1, CDC42EP5
cg17748184	1	Y_RNA
cg15733917	15	AC073046.25, AC079145.4, PTGFR, BCDIN3D-AS1, HCN4, CTB-176F20.3, MKL2, NBEAL1, SMG1, PLD1, CSRNP3, KAT6A, RP11-794P6.2, RP11-266L9.5, FAM208A
cg13551227	29	SRGN, RGS2, TNFAIP6, PLAUR, IFITM2, ICAM3, KRT42P, Y_RNA, LST1, TNFRSF1B, NAMPT, IL8, CTB-36H16.2, SKAP2, ACSS1, NCF2, ELOVL2, RNU6-111P, SLC16A14P1, LRMP, TMEM131, SOD2, C9orf163, LTB4R2, SDK1, DEFA3, BCL2A1, GPR135, WDR31
cg07252627	7	RMDN2-AS1, TMEM200B, RP11-1212A22.1, SORBS3, AKNAD1, RP11-142C4.6, C6orf118
cg22681114	275	CCDC147, APOBEC4, HYDIN, NHLRC4, C7orf57, OR7E47P, SLC22A4, INHBB, FAM154B, BBS2, TPPP3, WDR86-AS1, CCDC67, C1orf158, C20orf96, CXorf22, STOML3, FAM216B, UBXN10, GPR135, ARMC3, MS4A8, SPATA18, KIF24, HHLA2, SNTN, RABL2A, MORN2, C9orf171, RP11-57J16.1, RSPH1, TSPAN11, PCDP1, C17orf72, GPR162, CCDC170, IQCG, SHANK2, AK7, DYNLRB2, FTO-IT1, FMO3, TTC40, LRRC18, AIFM3, DNALI1, TUBA1A, RP11-428C19.5, MAP6, CDHR3, WDR96, C9orf24, CAPS, DNAH1, RBM14, RNF32, RP11-56A10.1, TIMP4, CROCC, EFCAB1, NEK11, AC079354.1, MDH1B, ZMYND12, TMEM107, KIAA1377, CTXN1, SPEF2, SRGAP3, FHAD1, CLMN, IFT46, AKAP14, SPATA4, TEK1, RFX2, LRTOMT, RP11-539I5.1, DNAH6, LPGAT1, C1orf87, CC2D2A, LDLRAD1, WDR78, C1RL-AS1, LRWD1, RP11-82L2.1, RP4-734G22.3, BZRAP1, PPP1R42, CCDC78, ROGDI, LDLRAD4, SNED1, RNF157-AS1, AC006273.5, IFT140, ARMC2, WDR86, ZC2HC1C, PCSK1N, AP000322.53, GRIN3B, MYB, CERKL, STMND1, LRRC46, RSPH4A, RP11-7O14.1, IGSF10, NWD1, DNAH9, RP11-150O12.6, WDR66, LYRM7, GSTA3, C1orf189, IFT172, RP11-128M1.1, MORN1, CTB-51J22.1, ZNF404, KDM4D, SRD5A2, RP11-445L6.3, DNAH10, SLC16A5, RP11-276H19.1, MCM2, AC005281.1, CYB5D1, CDC14A, C11orf88, CCDC88C, CDC20P1, CTD-2554C21.3, NRG2, GNA14, SLC23A1, FAM13A, ADCK4, SLC7A2, LA16c-313D11.12, WDR35, EFHB, C9orf163, KCNJ2-AS1, PTPRN2, PCDHAC2, DNAH3, MYO15B, SPAG6, ADH6, FOXJ1, IL5RA, ANKRD6, RP11-610P16.1, C1orf222, CNGA4, CNTRL, ENKUR, SLC47A2, TTC16, RP5-991G20.4, TSGA10, PZP, PRR18, SSC5D, PRSS12, ADGB, NR1I2, GDNF-AS1, RP11-318A15.2, LZTFL1, SENP8, C1orf173, MVB12B, DAW1, FGD5P1, ANKRD53, AC019064.1, TMEM121, RP11-454C18.2, AC002472.13, MLF1, WDR38, TPPP, NEK10, C14orf159, AC025171.1, FKBP10, WDR65, RP11-228B15.4, WDR16, TUBB4B, SMYD2, ZNF214, RP11-337C18.9, EID2B, TEK4, ERCC1, BBIP1, SRCIN1, PKD1, GALNT13, PIH1D3, HNRNPA1P34, UNC119B, TCTEX1D4, RP1-60O19.2, DCDC1, CAPN9, ADORA2B, CETN2, MYO19, FLRT3, PCDH19, PCDH7, NOLC1, CTB-36H16.2, RP11-214C8.2, CAPSL, LRRC48, PPIL6, CCDC81, CCDC39, DNAH11, EFCAB10, 38596, LINC00883, RP11-230L22.4, RP11-57H12.3, FILIP1, CLDN9, MORN5, AC002064.5, CCP110, AL360154.1, PCDH17, IGFBP2, RNASEH2B, CYFIP2, LINC01106, RP4-539M6.14, SPECC1, ANKDD1B, SCAF8, PAQR8, KIF6, ZFP90, GSTA2, TMEM131, FAM179B, C12orf75, CCDC146, AC144652.1, C5orf42, YJEFN3, TUB, CMBL, ENO4, RP11-150O12.3, CRIP1, TTC33, FAM174A, TTC12, TRIP13, SYTL3, ALDH3B1, PPP1R32, HS3ST6, SLC5A2, FAM83H-AS1, OXTR, CNKSR3
cg11298262	197	BCL7A, VEZF1, SLC27A2, DAK, LAMC2, IPO5, ATXN7L3B, HN1L, NWD1, CHL1, STEAP3, C12orf68, PRPF8, LRRC18, AC144652.1, RPTOR, TUBB4B, STAM2, PTGES3, AZIN1, CYP4B1, GRIN3B, ACO2, RP11-396J6.1, UNC119B, COL4A6, WDR31, RUVBL2, KLHL9, PRSS12, MEGF6, HMGN4, FUZ, SF3B3, HNRNPF, PRR18, RBM26-AS1, TRMT1L, TMEM131, DDB1, MTSS1, HSPD1, RP5-991G20.4, DYNC1H1, ZNF134, MGAT5, UMOD, EGFR, KRT8, PNMA1, IGFBP2, PRMT5, CCDC60, PTK2B, IGFBP5, LCA5, IFT140, PRR2B, RASSF3, CUL7, AHNAK, AMOT, ATP2A2, NEK9, ACSS1, NHLRC4, SUN1, CLIC2, CLDN16, FZD6, TXLNA, RASSF6, NOLC1, LINC00303, ITGB4, ADORA2B, SLC22A23, DMRT3, CLNS1A, RP11-106M3.2, METRN, NONO, TEK4, ERCC1, C14orf132, HSPG2, SRSF7, PCDH7, CSTF2T, PSD3, LRP1, SMOX, MIS12, SLC39A9, CAT, VWA5A, MIPEPP3, CES4A, MDH1B, SLC16A11, RP11-64D22.2, RMDN2-AS1, CTC-241N9.1,

		DPY19L4, PEX12, CCDC88C, FAM120A, GD11, TPGS2, SHROOM3, GTF3C4, DHX40, PHGDH, FOXK1, LRIG1, SCN4B, WDR11, CETN2, KDM4A, CHST9, STOML3, NCDN, ABCA13, BTBD3, TRIM2, ENPP4, UGDH, PODNL1, KB-1205A7.2, MMP10, CMTM4, RP11-7005.2, ZC2HC1C, JMJD7-PLA2G4B, AK8, RSG1, SENP8, FAM168A, ATP2B4, MSANTD4, PRRC2A, GSPT2, C14orf144, NGEF, WDR5B, RBMX, RP11-680N20.1, KCTD1, RP11-84D1.1, MAGED2, IMPDH2, ORAI3, SLC16A5, SPTLC2, INHBB, PRDX3, RPRD2, TUSC3, PCDHAC1, CELSR1, FAM53B, CLDN9, MT-TF, NTN1, EFNB3, RCAN3, AHNAK2, AKAP14, ASXL2, C19orf54, RP11-693J15.5, SLC23A1, CDS1, TM7SF2, TMA16P2, ILF3, HNRNPA0, SEMA3C, SREBF2, RNF157-AS1, ISYNA1, NAP1L2, DCTN4, NAMPT, CLSTN1, CAPS, ASB1, MT-TP, KIAA1671, MEPCE, PTPRF, ROGDI, EID2B, MS4A8, KIAA1377, ERCC6L, PCM1
cg06788631	5	AL133245.2, VCL, ITGB4, RP11-14117.2, LATS1
cg18471664	6	CX3CL1, SRGN, RGS2, CDH1, SLC2A10, MGAT3
cg09715562	35	SRGN, BCL2A1, LST1, PDE4B, RGS2, IL8, RP11-44F14.1, TNFAIP6, SIRPB1, TNFRSF1B, IFITM2, PLAUR, DEFA3, TNFSF14, CCDC26, RP11-19D2.1, CCDC147-AS1, LRMP, Y_RNA, SKAP2, RNU6-111P, HNRNPA1P52, HAS1, ICAM3, BOLL, CREB5, Y_RNA, PREX1, RP11-60E8.4, AL583860.1, CYTIP, ELOVL2, AC016910.1, RP11-256L11.1, DOCK2
cg05214404	2	RP11-219B4.5, AC079949.1
cg24669932	1	AC116609.1
cg20411278	2	RP11-96C23.5, USP49
cg18301742	128	FAM86HP, RP1-85F18.5, AC139100.2, PDE6B, CTC-241N9.1, TEX21P, WDR86, PIP4K2B, FAM182B, RP11-128L5.1, RP11-409C19.2, CTC-281F24.1, RP11-1212A22.1, RP11-128M1.1, NR1I2, NEURL1B, MCF2L-AS1, MIR4664, C3orf18, FAM181A-AS1, ZNF853, RP11-162G10.5, RP11-881M11.2, AC002064.5, CTB-187L3.1, AC005071.1, RP5-1103G7.4, ZNRF2P1, RP11-620J15.3, RP3-467N11.1, ITPRIPL1, ST6GALNAC2, SMIM6, HHATL, MRV1-AS1, AC068587.2, ANKRD6, RP5-1024G6.5, CNGA4, RP1-140K8.1, RP11-1191J2.2, MIR34B, AC062029.1, PCDH19, SERP2, NWD1, RP11-134G8.7, AKAP3, C1orf189, MB, CENPBD1P1, PRRC2B, RP4-758J18.7, C6orf118, FAM83H-AS1, LRMP, LINC00954, RP11-440L14.1, RP11-156K13.1, NEK9, ANKS1A, TMEM121, RP11-539I5.1, SMURF2P1, RPL23AP53, C1QTNF8, BCL7A, CTA-246H3.11, RP11-448G15.3, NOTCH4, RP11-645C24.5, TMCO6, NDUFA13, C14orf132, HCN4, RP11-452L6.5, RP11-727A23.5, RP11-536I6.1, LAMC2, RP11-508N22.12, TRIM2, FAM162B, ANKRD53, FCF1P8, CEP104, RP11-643M14.1, GJB7, LIMS2, KB-1047C11.2, COL6A1, RP11-104J23.1, EFCAB2, AC019064.1, RP11-20120.4, CEP250, FAM201A, CD5L, GHR, CLDN9, AL360154.1, HTR2C, MSANTD4, LINC00494, RP11-60E8.4, HSPA4L, AHDC1, MVB12B, KIAA0556, CCP110, KDM4A, KRT42P, C19orf44, RP11-296E23.2, LY96, LCA5, ZNF497, DPYS, APOBEC4, STK24-AS1, RP11-179B2.2, ZNF785, TEKT4, FTO-IT1, TUBB4B, RP11-454C18.2, NCKAP5L, ADH6, IFT172
cg26066560	1	PCDHGB7
cg09423080	37	LRRC55, PSG5, GLRX, FJX1, RP11-1082L8.3, SVOPL, SULF2, RP5-1063M23.2, NOTCH1, FMO3, SPARCL1, AC074011.2, COL4A6, RP11-486L19.2, PLEKHG3, WNT4, BCAM, KCTD12, RP11-219B4.5, EVPLL, TEKT4P2, RASSF6, ST3GAL5, FLNA, SRSF7, MARCKSL1, EGFR, WSCD2, CPNE4, NEU4, FAT2, IL33, KRT8P3, C10orf2, MB, CALML3, RHOB
cg05683632	6	RHOB, FLNA, FAM227B, GHR, UBE2C, TAF1
cg18900832	1	STARD9
cg16373535	5	RP1-127D3.4, RP11-111F5.5, FGD5P1, RHOB, RP11-384F7.2
cg27406678	24	BCL2A1, LST1, SRGN, TNFAIP6, CCDC26, CCDC147-AS1, IFITM2, SIRPB1, PDE4B, RGS2, TNFRSF1B, RP11-19D2.1, IL8, DEFA3, LRMP, RP11-44F14.1, SCML4, SKAP2, TRIM60P16, Y_RNA, ICAM3, CYTIP, SOD2, RP11-60E8.4
cg06301443	17	OIP5, FTO-IT1, RP11-645C24.5, TMEM121, CCDC152, PREPL, TMSB15B, TRABD2B, AC026806.2, CTC-436P18.3, SLC46A2, RP11-445P17.8, PCDHB1, RP5-1063M23.2, FTO, COLCA1, CCDC8
cg20256649	109	KRT42P, TMEM200B, ITPRIPL1, RP11-524H19.2, FLRT3, RHOB, AC007392.4, TMEM121, RP11-262H14.4, MARK2P13, PMFBP1, SLC1A4, GPR135, ZNF404, RMDN2-AS1, CBLN3, CTC-281F24.1, LRMP, RP11-3L10.3, CECR2, ST6GALNAC2, PHGDH, NRG2, RP11-312O7.2, AIFM3, CERKL, RP5-890O3.9, PDGFD, HNRNPA1P34, ZNF853, SLC16A14P1, ANKRD53, RP11-337C18.9, C6orf118, ANPEP, PAXBP1-AS1, RP11-428C19.5, CTD-2517M22.14, LDLRAD4, CTD-2132N18.2, NR2F2, PCDH17, DCSTAMP, SLC22A4, MMP10, RP11-645C24.5, ADORA2B, CNGA4, RP11-454C18.2, ACSS1, CCDC26, TNS1, LA16c-313D11.12, KDM4D, PCDHB5, MYO15B, RP11-401E5.2, TRABD2B, TRO, SMOX, RP11-1212A22.1, CTD-2555O16.2, ZBTB12, RBM14, HNRNPA1P12, GCNT4, CX3CL1, PCDHAC2, TRIM60P16, HHATL, GALNT13, RP11-867G23.9, C9orf163, CTD-3229J4.1, MSANTD4, CCDC67, FTO-IT1, SORBS3, COL4A6, FCF1P8, PART1, ZNF497, FOXD2-AS1, SDC3, RP11-296E23.2, RP11-57H12.3, HSPG2, AC116609.1, PKD1P5, AP005718.1, TSPAN11, RP11-173B14.5, IGFBP5, MT1M, CTD-2314G24.2, AP000322.53, MVB12B, OBSCN, ANKRD6, LPPR3, SF3A2, ADAMTS13, SSC5D, AC145212.1, NTN1, TNFAIP6, SNORD112, AC093702.1, EP400
cg21136271	24	BCL2A1, SRGN, PDE4B, LST1, RP11-44F14.1, RGS2, IL8, TNFAIP6, SIRPB1, IFITM2, TNFRSF1B, CCDC26, CCDC147-AS1, CREB5, RP11-19D2.1, PREX1, SKAP2, DEFA3, PLAUR, Y_RNA, TNFSF14, SOD2, ICAM3, PFKFB3

cg03010429	61	ELOVL2, BOLL, RP11-23E10.2, RP1-177110.1, TRIM61, CCDC147-AS1, AC016910.1, RNU6-111P, ACTBP8, IL7R, LINC00470, RP11-174M13.2, XKRYP6, CYTIP, CTAGE5, PLCXD3, snoU13, RP11-497H16.4, AC006227.1, AL583860.1, CECR2, RP11-554L12.1, RP11-373D7.1, AC007392.4, CD5L, HNRNPA1P52, DEFA3, RP11-60E8.4, NPTN, AKNAD1, SCML4, ICAM3, KB-1205A7.2, UBOX5-AS1, RP11-100L22.1, CTC-241F20.4, ARL6IP1P1, PCDHGA7, SNORD112, OR7A17, TNFSF13B, LRMP, DCSTAMP, CDH2, AC005399.1, RMDN2-AS1, RP11-256L11.1, RP11-720L8.1, RP11-578F21.12, MDFIC, RP11-561N12.2, NCF2, MIR4285, HTR3E-AS1, NPY1R, HAS1, PSPC1P1, COL24A1, DNAH17-AS1, PREX1, ANO5
cg09099761	48	BCL2A1, CCDC26, PDE4B, SRGN, LST1, TNFAIP6, SIRPB1, CCDC147-AS1, IL8, TNFRSF1B, RP11-19D2.1, TRIM60P16, IFITM2, Y_RNA, TNFSF14, PLAUR, CYTIP, XKRYP6, SKAP2, AC073065.3, RP11-44F14.1, RGS2, DOCK2, RP11-174M13.2, SERPINA1, ELOVL2, Y_RNA, DEFA3, RP11-23E10.2, PREX1, LRMP, LINC00297, AC007392.4, AC005399.1, RP11-693J15.5, CREB5, BZW2, CTD-3229J4.1, OR7A17, HAS1, SNORD112, RNU6-111P, CSF2RA, NPY1R, LINC00470, SOD2, GPRC6A, RP11-134L4.2
cg08369629	4	C1RL-AS1, CAPN9, INPP5B, RP4-614O4.11
cg06211272	7	ANK3, ST6GAL2, RP4-541C22.5, RP11-174M13.2, FTO-IT1, AC068610.5, SPTBN1
cg13469617	24	BCL2A1, SRGN, LST1, PDE4B, IL8, TNFAIP6, SIRPB1, RGS2, CCDC26, RP11-44F14.1, RP11-19D2.1, TNFRSF1B, IFITM2, PLAUR, Y_RNA, DEFA3, LRMP, CCDC147-AS1, TRIM60P16, SKAP2, SOD2, PREX1, ELOVL2, TNFSF14
cg16226507	5	HLA-DPA1, LGMN, FTO-IT1, GRM4, HLA-DRA
cg05095252	14	TNFSF14, LST1, SRGN, PLAUR, NCF2, RGS2, BCL2A1, IFITM2, IL8, TNFRSF1B, SIRPB1, ICAM3, PREX1, RP5-1119A7.14
cg17422500	3	RP11-19E11.1, SLC16A14P1, RP11-613M10.9
cg18918010	1	KRT8P3
cg23406506	1	AL354718.1
cg02151918	24	BCL2A1, PDE4B, LST1, SRGN, RGS2, RP11-44F14.1, TNFAIP6, IL8, SIRPB1, IFITM2, TNFRSF1B, CCDC147-AS1, CREB5, CCDC26, Y_RNA, SKAP2, PLAUR, DEFA3, RP11-19D2.1, PREX1, SOD2, PFKFB3, ICAM3, CYTIP
cg24714082	36	BCL2A1, SRGN, LST1, PDE4B, IL8, DEFA3, SIRPB1, IFITM2, RP11-44F14.1, TNFAIP6, RGS2, PLAUR, TNFRSF1B, SKAP2, TNFSF14, CCDC147-AS1, PREX1, SOD2, CCDC26, ICAM3, Y_RNA, Y_RNA, SERPINA1, NCF2, BOLL, HAS1, CYTIP, RP11-19D2.1, AC016910.1, AL583860.1, HNRNPA1P52, ELOVL2, ACTBP8, LRMP, DOCK2, SLC25A37
ch.7.3189261R	15	TNFAIP6, BCL2A1, CCDC26, SRGN, LST1, RP11-19D2.1, RGS2, IL8, SIRPB1, IFITM2, PDE4B, ELOVL2, RP11-44F14.1, CECR2, Y_RNA
cg18427648	2	GK-IT1, CSF2RA
cg14876117	1	RP11-1191J2.2
cg26744946	40	BCL2, TRIP13, CDC42EP5, MEGF6, CDC14A, IGFBP5, CNTRL, LRBA, S100A16, TSTA3, SYTL5, GAL3ST2, LDLRAD4, S100P, PBRM1, COL4A6, MYCL, RARRES3, ADIRF-AS1, BBS2, SECTM1, PCMTD2, SHANK2, CTD-2517M22.14, LPGAT1, MARVELD1, PDGFD, C4orf19, SNX29, ST6GAL2, ZNF853, VMAC, ABCC4, TMSB10, FAM179B, ARHGDIB, RNPC3, TAF1, LSAMP, SMOX
cg12823530	99	PCSK1N, ZMYND12, C6orf118, CCDC67, KIF24, NEK11, FTO-IT1, GALNT13, TMEM121, SLC22A4, MORN2, MCM2, NRG2, RP11-445L6.3, GPR135, RFX2, AIFM3, ARMC3, RP11-57H12.3, SPATA18, CAPS, CCDC78, RP1-60O19.2, CLDN9, APOBEC4, CTXN1, TPPP3, CCDC147, C20orf96, TTC40, SPECC1, RSPH1, C17orf72, RP1-151F17.2, DNALI1, NDN, CNTD1, BBS2, STOML3, MORN1, FAM216B, UBXN10, ZC2HC1C, IGFBP2, NHLRC4, C9orf24, MAP6, TSGA10, CTC-436P18.3, AC002064.5, FAM154B, CC2D2A, HYDIN, FLRT3, RP11-120M18.2, LDLRAD1, MDH1B, RBM14, CLMN, RP11-128M1.1, OR7E47P, RP11-228B15.4, WDR96, C9orf171, ANKRD53, DYNLRB2, CNTRL, FAM134B, FMO3, AKAP14, RP11-643M14.1, TTC16, AGR3, CXorf22, AK7, LRRC18, SERP2, ENO4, IQCG, C7orf57, TUBB4B, LRRC46, RP11-82L2.1, GPR162, FAM182B, GRIN3B, LRTOMT, CCDC170, TUBA1A, KCTD17, DNAH6, MIR34C, RNF157-AS1, HHLA2, SPAG6, MORN5, IFT172, CCDC178, SPEF2
cg07906473	1	ACSS1

Supplementary Table 13. List of disease associations from genes identified as part of the differential gene expression and methylation correlation analysis. There were over 500 associations and therefore only those related to the respiratory system/lung are shown for clarity.

Diseases Annotation	P-value	Genes
Primary ciliary dyskinesia	4.33E-09	13
Nonsquamous non-small cell lung carcinoma	3.66E-06	125
Small cell lung carcinoma	5.20E-06	138
Lung adenocarcinoma	7.78E-06	123
Malignant neoplasm of respiratory system	1.26E-05	257
Lung carcinoma	1.42E-05	230
Lung cancer	1.58E-05	235
Non-small cell lung carcinoma	8.64E-05	152
Large cell lung carcinoma	5.78E-04	12
Laryngeal squamous cell carcinoma	6.18E-04	39
Non-small cell lung adenosquamous carcinoma	1.10E-03	6
Chronic familial respiratory disorder	1.14E-03	5
Recurrent large cell lung carcinoma	1.24E-03	4
Undifferentiated lung carcinoma	1.35E-03	13
Recurrent EGFR sensitizing mutation positive non-small cell lung cancer	1.92E-03	4
Upper airway cancer	2.18E-03	66
Persistent nasopharyngeal cancer	2.35E-03	4
Unresectable EGFR sensitizing mutation positive non-small cell lung carcinoma	2.35E-03	4
Sinus disorder	2.47E-03	10
Metastatic squamous cell cancer of the ethmoid sinus	2.84E-03	4
Metastatic squamous cell cancer of the glottis	2.84E-03	4
Metastatic squamous cell cancer of the maxillary sinus	2.84E-03	4
Metastatic squamous cell cancer of the supraglottis	2.84E-03	4
Recurrent squamous cell cancer of the ethmoid sinus	2.84E-03	4
Recurrent squamous cell cancer of the glottis	2.84E-03	4
Recurrent squamous cell cancer of the maxillary sinus	2.84E-03	4
Recurrent squamous cell cancer of the supraglottis	2.84E-03	4
Unresectable squamous cell cancer of the ethmoid sinus	2.84E-03	4
Unresectable squamous cell cancer of the glottis	2.84E-03	4
Unresectable squamous cell cancer of the maxillary sinus	2.84E-03	4
Unresectable squamous cell cancer of the oropharynx	2.84E-03	4
Unresectable squamous cell cancer of the supraglottis	2.84E-03	4
Stage IV ALK translocation positive non-small cell lung cancer	3.20E-03	5
Stage IB primary non-small cell lung cancer	3.39E-03	4
Stage II primary non-small cell lung carcinoma	3.39E-03	4
Unresectable squamous cell cancer of the hypopharynx	3.39E-03	4
Lung squamous cell carcinoma	3.49E-03	55
Locally advanced nasopharyngeal carcinoma	4.01E-03	4
Non-keratinizing nasopharyngeal carcinoma	4.01E-03	4
Stage IIIA primary non-small cell lung carcinoma	4.01E-03	4
Primary non-small cell lung carcinoma	4.09E-03	5
Unresectable recurrent non-small cell lung cancer	4.62E-03	6
Primary non-squamous non-small cell lung carcinoma	4.70E-03	4

Supplementary Table 14. Downstream functional effects analysis results from genes identified as part of the differential gene expression and methylation correlation analysis.

Functions Annotation	P-value	Genes
Microtubule dynamics	5.54E-10	47
Formation of cellular protrusions	1.19E-09	38
Formation of cilia	2.74E-09	23
Organization of cytoskeleton	3.01E-07	52
Organization of cytoplasm	1.01E-05	54
Formation of axonemes	4.48E-05	4
Shape change of endothelial cell lines	6.78E-05	5
Cell movement	1.06E-04	78
Metabolism of reactive oxygen species	1.68E-04	20
Synthesis of reactive oxygen species	2.53E-04	18
Generation of reactive oxygen species	4.22E-04	9
Metabolism of superoxide	5.57E-04	4
Stimulation of cells	6.04E-04	10
Transport of sugar acid	7.80E-04	3
Uptake of ascorbic acid	8.41E-04	2
Transmembrane transport of ascorbic acid	8.41E-04	2
Migration of cd56+ natural killer cells	8.41E-04	2
Quantity of cytoneme	8.41E-04	2
Binding of muscle cells	1.24E-03	4
Stimulation of leukocytes	1.60E-03	8
Targeting of vesicles	1.79E-03	3
Migration of cells	1.93E-03	66
Calcium homeostasis of endoplasmic reticulum	2.51E-03	3
Apoptosis of epithelial cells	2.69E-03	9
Degranulation of granulocytes	2.84E-03	4
Movement of cilia	2.84E-03	4
Cell death of epithelial cells	3.56E-03	12
Stimulation of mononuclear leukocytes	3.81E-03	7
Cell spreading	3.96E-03	9
Assembly of non-motile cilium	4.40E-03	3
Adhesion of muscle cells	4.40E-03	3
Binding of AP1 consensus site	4.70E-03	4